[
["index.html", "Summary of Conferences 2016 Chapter 1 Introduction", " Summary of Conferences 2016 Sungpil Han, M.D./Ph.D. 2017-03-21 Chapter 1 Introduction Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here. "],
["section-2.html", "Chapter 2 심장내과", " Chapter 2 심장내과 [Ekg] 정상 ekg 읽는 법. V1에서 S만 보여. 뭐지? 정상이 과장된 상태. LVH다.. LBBB wide qrs wpw - short pr lv infarct. ant Q, reciprocal. RBBB RVH WPW RIGHT. MI POST LBBB LVH WPW LEFT. MI ANT st elevation. pericarditis. normal male pattern T wave inversion. LBBB환자에서 T inv가 있는데 추후에 qrs방향과 맞게 바뀌었으면 infarct의심해야 한다. [Echo 송재관] 초음파 60년전. Long axis. Short axis. Apical view. Subxyphoid view. SAM. w LVOT. Pulsed doppler. 앵두같은 MS. 2.5Hz TTE. 해상도 높으면 penetration이 낮다. Effort chest pain. Cardiac CT 연세대 최병욱 [Chest pain 연세의대] Stress test? 한번더 잘 생각해 보자… 특징적인 angina | atypical angina CCS angina. III,IV이상을 typical Resting angina | Increasing angina TMT? Treadmill test Non invasive risk stratification 위험군- ST depression at stage | Exercise induced VT/VF Early invasive diagnostic W/U | Strict warning 언제든지 잘못될 수 있다 !!! Arrest &amp; CPR - Careful hx -&gt; 실제로는 간단한 환자가 아니었어..!! NSTEMI (DM+HTN) !!! Early invasive - Resting angina | CHF symptoms, S3 gallop | EF&lt;40% | VT | Vital instability | TnT(+) | TIMI&amp;GRACE score가 높은 경우 쓰라리다. 욱신거린다. 하루종일 아파. 여기가 아파. (비전형적) VS 돌로 누른 듯 묵직. (전형적) 괜찮은 줄 알았던 사람인데 알고보니 D-DIMER(+) -&gt; PTE 전혀 괜찮을 줄 알았는데 알고보니 Aortic dissection 게이 | 37남 | vasospastic angina? | 그러나 당일 오전 악화된 통증은? 갑자기 나타난 고혈압? | 이차성 고혈압??인가? | Renovascular -&gt; Aortic dissection….으로 최종 진단됨. class B Take home message - CT 찍는걸 주저하지 마라. 김영탁 - 울산의대 “invasive and functional eval of IHD” 증상없으면 angiography or CT angio -&gt; inappropriate! 기능적 ischemia 침습적 검사 - Good|anatomic information, Tx+Dx vs Bad|hospitalization, cost FFR - 0.75이하이면 significant stenosis DEFER study-FFR&gt;0.75일때 - 괜찮아.. 이걸 근거로 PCI할 경우 생존율 증가. INCIDENCE 감소 FFR이 치료 방향을 결정해 준다. 성인 남자는 흉통이 있으면 TEST해야한다. INTERMEDIATE RISK라고 할 지라도.. 해봐야 한다. 젊은 여자는 안해도 돼. CARDIAC IMAGING - STRESS EKG못할 경우에 유용. 운동부하 심전도는 병변의 위치 알 수 없다. ANGINA 보다 PERFUSION의 감소는 먼저 DETECT 할 수 있다. Cardiac 엠알은 비싸고 관상동맥 보기엔 좋지 않다. !!! FFR-CT는 간접적이지만 Radiation적다. computational fluid dynamics. sensitivity(있으면 있다) 높다. specificity(없으면 없다) 낮다. 허혈 여부가 중요. SPECT가 많이 쓰이고 있다. [치료 - 협심증 - 울산의대 안정민] 약물치료 + 혈관재개통 또는 수술 | 딱 두가지다! !!! 안정형 협심증 - 약물이나 스텐트나 사망률은 완전히 같음 (7년) - 스텐트 할 필요 전혀 없음 !!! STICH - 수술과 모탈리티 차이 없어. ASPIRIN - CAD, CVA, CABG - REDUCTION OF DEATH Clopidogrel - death, MI, stroke ASA보다 낮춰줘야함. 출혈 경향은 좀더 크다. !!! DUAL ANTIPLATELET이 중요하다. BB - SA에서 좋다 ACEI - NO ANTI ANGINA EFFECT | HTN, DM, 신장기능 안좋을때 꼭 써야함. NITRATE - 심장에 인삼같은 약이다. BB,CCB와 함께 ANGINA완화함 STATIN - 굉장히 좋은 약. 필수적임. !!! OMT ( optimal medical Tx) - 1개 statin. BB. ACEi/ARB. 네개 꼭 써야한다!!! 50%도 안하고 있다. 잘 챙겨야 한다. 하지마라. - estrogen, Vit C, Vit A 등은 증거가 없고 해로울 수도 있다. 두단계 - 허벤, 베라파밀 Non-DHP CCB + BB -&gt; Statin TMT Gr3 잘 하면 약물. 1단계 페일하면 invasive !!! non invasive functional study 해야 한다. - risk stratification해서 약물치료 or 스텐트(수술)해야할지 !!! 조지 부시 - 증상 없는데 스텐트 해야할까? 안해도 된다. 현재 기준으로는 over-use stent 무분별한 CAG가 많으므로 증상없으면 안해도 돼. 저위험에서도 안해도 됌 ISCHEMIA연구 - CAG 없이 약물 혹은 혈관재개통? - 무엇이 좋을지… Everlorimus-eluting stent angiography뿐만 아니라 FFR guided PCI를 해야한다. FAME연구 - 스텐트 과다 사용을 낮춰준다. BRS - 몸에서 저절로 흡수되어 사라지는 스텐트 - 5년 뒤엔 완전히 없어져. PCI VS CABG | 단순병변 VS 복잡병원 (3VD, LM+2 OR 3VD) NIFS - NON INV FUNC STUDY (TMT,THALLIUM) - LOW(OMT) VS HIGH (CAG+OMT) - PCI, CABG [ACS UPDATED MANAGEMENT] 히드라 80세 이후엔 암으론 잘 안죽어. 혈관으로… !!! 레벨 A- ANTI PLT, STATIN, ANTI-HTN !!! !!! TROPONIN - 0.04가 기준이다!!! 애매하면 coronary CT 찍어라. -&gt; suspicious ACS at ER. 20분이상 STE. 2개 리드에서.. 10% | 20% | 10% - stemi|NSTEMI|UA P2Y12 - PLT ACTIVATION BLOCK - TICAGRELOR,PRASUGRL,CLOPIDOGREL(STEMI) IABP X 쓰지마라.(AMI with mechanical Cx-VSD) - NE!!!(LEVOPHED) - DOPAMINE 안쓴다. !!! TIMI쓰지마라. GRACE (ACS RISK SCORE 2.0)가 좋은거다!!! Time is Muscle. 5% mortality - door-to-door time 줄어도 동일하다. !!!! 환자가 빨리 와야된다. !!!! 혈전용해제는 뇌출혈 없으면 다 해야된다. !!! statin. dual. BB 정리 Medical Tx가 중요하다! - survival rate를 높이는 스텐트는 제한적인 population에만 적용될 수 있다. 청진기보다 초음파보는게 중요한 시대가 왔다. 청진기가 필요없다. subjective Sx "],
["-3.html", "Chapter 3 심장내과 3부", " Chapter 3 심장내과 3부 [Mitral Valve Disease - Dx and Management - 김덕원(울산의대)] MR - 피가 역류하므로 좌심방 좌심실 커진다. 심부전 1차성 - 퇴행성, 류마틱, 선천적, 심내막염 | 2차성 초음파검사가 중요하다. 병기는 A/B/C/D - C/D는 SEVERE. Primary Severe MR - anatomy. Hemodynamics. LV enlargement. Echo for degenerative MR - myxomatous degeneration. ERO&gt;0.4cm^2 | LV EF&lt;60% MV repair - 사망률 줄였다. 64여 - known DM - Dyspnea(+) - 4MA - global hypokinesia (akinetic portion) - structurally normal - tethering (땡겨지는 현상) - Severe functional MR. ERO &gt;0.2cm^2 !!! 1차성은 적극적으로 치료, 수술 고려한다. 그렇다면 2차성은?? 여전히 수술 후 사망률이 높다. 좌심실이 중요한 예후인자이다. 수술후 생존률에 이득이 있지는 않아. 이득이 제한적임 !!! MS - natural hx. - 진행이 매우 느리다. INDOLENT. 좌심방에 PR. OVERLOAD - 그러나 심방세동이 발생하면 갑자기 안좋아지는 경우가 있다. 그러나 대체로 예후 좋다. 증상없으면 두고보는데 세동 생기는지 잘 관찰해야 한다. AFIB 생기면 STROKE생길 확률 매우 높아진다 (치료안하면 &gt;90%) PMV가능할 경우 PMBC- PERCU MITRAL BALLOON COMMISUROTOMY. 불가능할 경우… 증상없는 심한 MS. PMBC - Septal puncture- 가장 위험할 수 있다. hemopericardium생길 가능성이 있다. embolism. severe MR.등의 합병증이 생길 수 있다. 이미 혈전이 있으면! 하면 안된다. 합병증 줄이려면 - case operation experience가 중요하다 | patient selection 잘해야 한다. Early PMC [송종민 - Aortic Valve Ds - Dx and Mx] AS - ETIOLOGY - degenerattion. calcification. thickening. 열릴수가 없는 상태이다. bicuspid leaflet. Pr. gradient of as. 크면 클수록 AS심한거다. 요즘엔 도플러를 통해 버눌리 방정식으로 구한다. AV 속도가 중요한 위험인자. VERY SEVERE MS+LOW SURGICAL RISK - 미리 수술하는게 가능. !!! TAVI VS Medical Tx TAVI가 좋다 (PARTNER Trial) 2011 NEJM TAVR vs SAVR 차이 없다 - 요즘엔 CORE VALVE(Self expandable 늘어나는 신축성 있는거)로 해보니 TAVR이 모든 면에서 좋아! AR - 수치화 하는게 중요하다! 복부대동맥에서도 보이면 severe 수술 늦게하면 나쁘다.. 너무 늦게하면 좋지 않아. EF낮으면 예후 나쁨. LVESD낮으면 예후 나쁨. VASODILATOR (NIFEDIPINE) - 초기에는 좋다! - 이후엔 별 차이 없다. AR+HTN은 약물치료해야한다. 수술해야하는건 결국 고려해야 한다. [SCD Evaluation - 성균관대 박경민] 갑자기 쓰러짐. 왜 쓰러진걸까? Normal coronary일때 - 부정맥 전문의들에게 큰 문제가 생긴 것임. DDX OF SYNCOPE | CARDIAC 20%이상의 돌연사 확률 (1년 이내) EVALUATION - Hx. FHx. Drug- prolonging QT interval(cisapride, 초오aconitum - 한약 먹었는지 물어봐야) 돌연사의 가족력!!! -&gt; 미주신경성 (복부, 식은땀, 회복기때 구역, 서있을때 실신) vs 심장(누웠을때, 운동중) 비침습적 - EKG. precordial lead. - 전해질? | 초음파 HCMP, VHD, LV, ARVC/D | MR | HOLTER, EVENT RECORDER | Implantable event recorder(3년) 침습적 - cardiac cath. - spasm test(젊은 사람의 경우) EPS 유발시킬 수 있는가? 잘 안되는 경우도 20-30%된다. ㄱ브루가다 - Precordial lead ST가 자주 변하는 경우 증상: 실신 - 피지컬, 이미징 정상 - ECG - FLECAINIDE, PROCAINAMIDE - NA CHANNEL BLOCK. CURVED PATTERN이면 확진가능하다. SADDLEBACK PATTERN 이면 좀더 두고봐야한다. Long QT syndrome - QTc - RR interval QT/sqrt(RR interval) - 소타롤 등등, 420mm이상이면 롱. - 젊은 사람 - TdT 잘 생긴다. 롱큐티에서 TDT 잘 생길 수 있어. 저칼륨, 저마그네슘, 할돌 항고혈압제, 에리스로마이신 LQS 1 exercise(swimming) | 2(깜짝 놀랄때) | 3(잠자다가 실신) - 처방 : 베타블로커, 수영 덜해라. 약물 줄여라. BB - LQS 1,2에 잘 듣는다. 급사가족력. 젊은 남자. VTACHY. DC CARDIOVERSION 후 심전도에 찌글찌글 - ARVD/ARVC - SUDDEN CARDIAC DEATH가능함. EPSILON WAVE. ARVD진단기준. - 영상검사. BX - 도움된다. 심실 제세동기 삽입이 치료! 실신. 젊은 여자. 아무것도 안나와. 전기생리학적 검사 거부. 모니터 삽입. VT - 심실제세동기 삽입. "],
["cancer-immunotherapy.html", "Chapter 4 Cancer immunotherapy", " Chapter 4 Cancer immunotherapy Image Image 2016.04.04.Tue 대강당 지하1층 Donor NK cell therapy for refractory acute leukemia - 이규형 (서울아산) - NK cell 조기에 줬더니 합병증 있었다. 열이 났다. weight gain Cytokine syndrome 그러나 착상은 잘 된다. - bilirubin 올라가기도 했다. - 45명 -&gt; 33명이 cytokine syndrome 12명은 안생겨 (19명은 complete, 3명은 백혈병 나빠져, 3명은 multi organ failure로 사망) - ATG level은 낮아져. IL-15은 점차 상승해 - nkp40 receptor 낮으면 재발. - DN - CD56- : 1/1000이 아마 contaminating T cell이 있지 않을까? - Randomized study 하고 싶다. IIT에서 SIT로 하고 싶다.. - CAR NK 세포 1-2상 임상시험. (SIT) - Q) ALL이 성적이 나쁜 이유는 무엇? A) Tumor별로 다르다. 정도.. - Q) CAR NK를 공부하다보니 saline을 이용한 시도? A) 가능하구요.. shelf에서 꺼내 쓸 수 있어 장점인데 아직 모른다.. 오리무중 상태.. Turning tumor mutations into personalized cancer therapies. - Roman Yalensky (Gritstone oncology) Genetic instability is a - immune checkpoint inhibitors -&gt; CPI ground-breaking - - Overall survival in NSCLC patients | docetaxel vs nivolumab (Anti-PD-1 mAb) - both are poor (24mo) - Question ) why? some are responsive others are non-responsive. - highest mutated cancer - mutations are relevant to CPI mechanism of actions (Rizvi 2015 Science) - TSNA first class of altered (non) self antigen | Non-self가 less risk of therapeutic failure due to immune tolerance (Tumor-specific net-antigens) - Snyder 2014 NEJM - IFNg+ T cell response - (mutation) - anti CTLA4 - Vaccine | Tumor infiltrating T cells are CD4 and Vb22+ - Bx-seqeunceing-manufacturing | personalized process - Nucleic acid | synthetic long peptide | virus | cellular - Selecting new antigen | - HLA-IP/MS - 7/170(4%) - &lt;1 in 20 predicted HLA-bound neoantigens are presented by tumors (Gros) - nature med 2016 http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4051.html - Exome and T txTome &amp; tumor MS HLA peptide sequencing - FFPE tissue specimens | Translational Research of immune-oncology in real world - 정헌 (MSD) - Immune monitoring 꼭 필요하다. - MSD Oncology Medical Director - PD-1/PD-L1 pathway development (20년) Dr.Honjo가 발견 - ipilimumab (Mono) - melanoma 3y OS|~20% - Combination regimen (Optimal combination) - Biomarker | Combination rationale | New immune modulator - Enough resources + regulatory support + collaboration + clear objective + straightforward operation + agility flexibility + right IO target identification + irTME understanding + material archiving - responder group찾고 관련된 target, pathway를 찾는다. - combinational - 400여개의 trial 이 이뤄지고 있다. coinhibitory보다 costimulatory가 훨씬 어렵다. - antiCD137, antiPD-1, antiOX40 - Keynote (biomarker) - Hurdle - 1 Gap of immune related TME between human and animal | CD28 - mouse ? - 2 immune monitoring이 중요하다. - 3 evaluation of CD8+ TEM cell - CD45RO+ memory(responder) - 4 Inadequate tissue quality and volume (20%가 necrosis, fibrosis) - 5 SOC discordance (US and Korea) - 6 different Ab or platform - 7 FFPE - Gene expression signature - platform 찾아야. - 8 gap between leading countries and second runner in IO (US - 4 pathway segment, 9 products segment) - simple and easy to understand "],
["bioimaging-2016-04-29.html", "Chapter 5 Bioimaging 2016-04-29", " Chapter 5 Bioimaging 2016-04-29 Lee, Hanmi | Value of Bioimaging for global drug development B-raf inhibitor | targeted inhibitor * Anatomic-functional-&gt;molecular(optical imaging, IVIS, SPECT, microMR,PET,CT * Bioimaging platform | PK, Imaging biomarkers, treatment effect, diagnostic tools * PD-1 | IHC system (digitalized and standardized) immune-oncology - PD-L1 expression - Pembrolizumab (MK-3475) - NSCLC * Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer http://www.nejm.org/doi/full/10.1056/NEJMoa1501824 * Biomarker discovery - surrogate marker &amp; PK/PD * Human PK | exposure response PK-PD(Target engagement) | Exposure-safety [HM95573] BRAF-KRASmut inhibitor http://www.newstown.co.kr/news/articleView.html?idxno=185364 한미약품이 개발 중인 차세대 표적항암제 HM95573이 국내 1상 임상시험에 돌입한다. 한미약품(대표이사 이관순)은 최근 HM95573에 대한 임상시험 승인 신청서를 식품의약품안전처에 제출하고, 내년부터 서울아산병원에서 흑색종 등 고형암 환자를 대상으로 임상 1상에 돌입한다고 5일 밝혔다. HM95573은 암세포 증식 및 성장에 관여하는 변이성 RAF 및 RAS 단백질을 선택적으로 강하게 억제하는 표적항암제로, 기존 약물에 반응하지 않거나 부작용이 큰 환자들에게 투여할 수 있는 2세대 RAF 저해제 약물로 개발되고 있다. 한미약품은 이번 임상을 통해 고형암 환자에서 HM95573의 안전성과 내약성을 평가해 최대 내약용량 등을 결정하며 종양반응률, 최대 종양크기 변화율, 질병조절율 등을 관찰하게 된다. 약물의 종양 반응과 관련한 시험 대상은 변이성 B-RAF, 변이성 K-RAS 및 변이성 N-RAS 단백질을 가지고 있는 흑색종, 대장암, 간암 또는 비소세포폐암 등 환자이다. 한미약품 정진아 임상개발 담당이사는 “HM95573은 기존 항암제에서 반응하지 않는 환자들에게 투여할 수 있는 2세대 약물로 개발 중인 표적항암제“라며 “암으로 고통받는 환자들에게 혁신적인 치료제가 될 수 있도록 최선을 다해 개발하겠다“고 밝혔다. 한편, 이번 HM95573 개발은 지난 2013년 6월부터 보건복지부의 ‘국산 희귀의약품 연구개발 과제’로 선정돼 보건의료기술연구개발사업의 지원을 받아 추진된 것이다. 한미약품은 HM95573을 비롯해 암세포 성장에 관여하는 EGFR(상피세포성장인자) 돌연변이만을 선택적으로 억제하는 ‘HM61713’, EGFR 수용체의 신호전달을 차단하는 포지오티닙(Poziotinib) 등 3건의 표적항암제 파이프라인을 보유하고 있다. https://clinicaltrials.gov/ct2/show/NCT02405065 BRAF Mutant Melanoma Only -&gt; Vemurafenib, Dabrafenib FRET - measures signaling PD marker - efficacious dose = 300mg BID | MODELING | POP-PK expected efficacious exposure ~130k c.a Pan EFGR inhibitor or - Afatinib, Erlotinib - live in vivo imaging Summary - longitudinal in-vivo imaging 28 programs | Total R&amp;D center : 493 [Q&amp;A] Companion diagnostics - targeting angiogenesis "],
["-fda-.html", "Chapter 6 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 | 6.1 김정곤 Center for Bioimaging of New Drug Development AMC", " Chapter 6 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 | 6.1 김정곤 Center for Bioimaging of New Drug Development AMC Qualification 왜 이미징바이오마커에 대해서 qualification 필요한가? Bioimaging의 논문수는 기하급수적으로 증가중 누구나 인정가능한건가? Biomarker - a characteristics that is objectively measured and evaluated as an indicator of normal biological proc, pathogenic proc or pharmacologic responses to a therapeutic agent Surrogate endpoint - a biomarker that is intended to serve as a substitute for a clinical meaningful endpoint 최종목표 correlated to clinical outcome Validation = reproducibility | 확산강조영상DWI - tumor에서 measure할 수 있나? Qualification = linking a biomarker with biological proc Trial investigators often do not know - where | what QC testing performed? | What sources of bias &amp; uncertainty in measurements Inadequate QC Inconsistencies in the imaging protocol FDA Drug Development Tools DDT Qualification Programs http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ CDER | CDRH - FDA에서 관장. OND - 약물 개발 과정의 규제 감독. 신약 판매 허가. 6개의 사무실로 구성 http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm184426.htm 궁극적으로 encouraging Biomarker Qualification Program http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm230597.pdf Qualification Process for Drug Development Tools APPENDIX 1: QUALIFICATION PROCESS European Medicine Agency | 일본에도 있다. Current Status of Imaging BQ 6/16 BQ submissions are on imaging biomarkers "],
["kscpt.html", "Chapter 7 2016 KSCPT 7.1 First Session 7.2 Second Session", " Chapter 7 2016 KSCPT Materials Opening Remark - Yil-Seob Lee (president of KSCPT) 7.1 First Session Chair : Deborah Chee(KoNECT) 7.1.1 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective Speaker: Munir Pirmohamed (University of Liverpool, UK) Fava beans - Favism G6PD deficiency - withrawal of antimalarials 2015 Obama Precision Medicine $215m / 2016 China $8b Phenotypic definition(current standard) - Molecular definition (disease stratification) - Drug variability Mandatory genomic testing - EMA SmPC Pharmacogenomics Journal (2015) 1-10 Crizotinib vs CTx in advanced ALK+ lung cancer (NEJM 2013) Novel trial design (Nature 2015) Umbrella trial (single tumor - multiple arm - multiple drugs) Basket study Support of humen genetic evidence for approved drug indication (Nature Genetics) Sclerosteosis - skeletal overgrowth and syndactyly, AR , mutations in SOST gene - target sclerostin anti-sclerostin Ab (ROMOSOZUMAB, BLOSOZUMAB) - bone density increase - mouse New cardiovascular targets PCSK9 - GOF-&gt;LDL-C increase &amp; CVD ANGPTL4 HLA-genotype and carbamazepine-induced cutaneous ADR: systemic review (CPT,2012) ITCH (Drug hypersensitivity) Phase I, II - very strong association (Manhattan plot) - GWAS - ALK(germline polymorphism-&gt; T cell expansion) SJS GWAS (Genin 2011) http://www.ncbi.nlm.nih.gov/pubmed/21801394 Skin, Liver CBZ-induced hypersensitivity vs CBZ-tolerant patients HLA-A*31:01(thirtyone o one) HLA and ADR The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. (2016) http://www.ncbi.nlm.nih.gov/pubmed/26478982 Somatic genomes -&gt; microbiome is also important Digoxin and antibiotics (1981, NEJM) -&gt; (2013 Science) Cardiac drug inactivation by human gut bacteria Microbiome and Cancer Immunotherapy - Snyder, Science Nov 2015 Two books introduced. Prescription for nhs clinical pharma dynamic medical specialty 7.1.2 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice Speaker: Shiew-Mei Huang (North Potomac, MD, USA) CPIC (Clinical pharmacogenetics guidelines) IFNL3(IL28B) HCV treatment Favorable response = 77% Asian (Genotype CC) Paving the way for Personalized Medicine (Oct 2013) Avacavir HLA-B*5701 (RCT) Utility of pharmacogenetic tests Munir mentioned - CBZ &amp; HLA-B*1502 ASCO meeting - CTx vs Targeted therapy - Umbrella study Drug labeling “FDA-approved test” XALKORI - Crizotinib and ALK CPT Feb 2016 - Precision Medicine , “Companion Diagnostics” Something unique to conduct , “Complementary diagnostics” Eliglustat and CYP2D6 , Drug labeling Center for Device Integral to the future of personalized or precision medicine NGS PrecisionFDA initiative 23andMe - Drug response , Confidence Cleared or approved FDA CLIA-certified laboratory My Question - One NGS - individual test to is there a review of all-in-one Test in progress? 7.1.3 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology Speaker: Eric Chun Yong Chan (National University of Singapore) Liver - major organ for disposition and detoxification 60% (explanble) vs 40% (how about this?) - superorganism 400 different species (~1.5kg) Haiser (2012, Science) Gut microbe - drug, host interaction TOC: 1 DMD paper , 2 in-house project DMD - reduction, hydrolysis absorption - simvastatin - poor responder, average, good 10% 80% 10% OATP1B1 in liver and intestine Possibility of competition between simvastatin and bile acids for hepatic uptake by transporter antibiotics - nitro-reduction by gut microbiota inhibition Therapeutic fficacy - DDI PCA analysis PNAS 2009 - significant differences in concentration PNAS 2009 inverse corr - p-cresol &lt;-&gt; AAP 2nd part - Tacrine - first drug approved for AD. Toxicological manifestation - increased AST/ALT Interindividual variability. why? Tacrine metabolism - hydroxylation / glucuronide mitochondrial toxicity and hypoxia-reoxygenation part I~V Tacrine-induced transaminitis EXT - CMax,AUC high why? - phase II metabolite? host gene - mRNA GC/TO PCA analysis principal component analysis NORMAL Lactobacillus EXT Bacteriode Blautia Metagenome level Liver - Tacrine-&gt; TacrineNGlucuronide 7.2 Second Session Chair : Yong-Bok Lee(Chonnam National University) 7.2.1 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers Speaker : Eileen Dolan (The University of Chicago, USA) Ototoxicity, CTx Toxicity - hearing loss, peripheral neuropathy dose-limiting toxicity - platinum, taxanes, vinca, epothilones, bortezomib numbness, tingling, burning/stabbing pain partially , can be permanent Duloxetine - SNRI - CIPN pharmacogenomic studies - optimal model - testicular cancer - platinating agents CIPN - &gt;300mg/m2, dorsal root g. cell apoptosis, affects large neurons, axonal projections CTCAE of CIPN, patient-reported measures preferred (CIPN EORTC-CPIN20) PCA analysis age, smoking GWAS - CIPN6 -&gt; CAMTA1, RGS, WDR1, MAPK9, COA1, ILR2A Polygenic architecture PIPN : ECOG: rs3125923 Stem cells - problems - identifying, priortizing cell-based PD analysis iPSC technology in PGx, CRISPR Neuronal measurements - total outgrowth processes, process length, branches, cell body area C, P, 5FU, Bortezomib, Vinc, Thalidomide inhibition of neurite outgrowth VIN - GWAS 2000 patients CEP72 - microtubules assembly, TT allele - susceptible -&gt; lower CEP72 mRNA expression knockdown of CEP72 in iPCSC -&gt; enhancing sensitivity to vincristine 7.2.1.1 Questions - neurite outgrowth Neurons- mature enough? 7.2.2 15:50~16:20 Pharmacogenomics and Epigenomics Speaker: Matthias Schwab (IKP Stuttgart, Germany) Prognostic predictors Genetic make-up 135 FDA-approved drugs with labeled pharmacogenomic information (2015-05-20) top 30 drugs with pharmacogenetic risk (w/ or w/o high-risk diplotype for gene) Genomics, proteomics metabolomics, microbiomics Genome Medicine 2016 (Auffray, Schwab) NEJM Cocktail approach - a single dose PK study - old fashion clinical pharmacology approach? - Metoprolol and Torsemide PK - heretability Koryza Genet Med 2016 - comprehensive analysis - ESP project (n=6500) and 1000 genomes project PNAS 2005 Fraga - Epigenomics and DNA methylation miRNA, methylation, histone modification(acetylation) CPT 2016, Fisel, Schaeffeler, Schwab - DNA methylation and its impact on disease pathophysioloy and drug therapy Heatmap - ADME genes - SLC transporters My Quesion - Can we develop therapeutics which target locus of epigenetic (Decitabine)- Renal cancer cell - treatment of decitabine - demethylating agents (Specificity?) - Epigenomics 7.2.3 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis Speaker: Young-Jin Chun (Chung-Ang University, KOREA) P450 (CYP1B1) Estrogen metabolism : E2-&gt;4-OHE2(endogenous mutagen) ZYC300 cancer vaccine - CYP1B1 DNA Vaccine Immunity to CYP1B1 -&gt; Clinical benefit 과발현시 - PCNA increased TMS - specific human CYP1B1 - DMBA-&gt;PPCNA increased, DMBA+TMS-&gt;PBNA back to normal CYP1B1 -&gt; EMT (ECADHERIN, ZEB1, Vimentin, twist1 ) FUNCTIONAL STUDY , Can we transmembrane migration - cancer progression SP1 Transctiption factors - Mithramycin A(binding inhibittor) DMBA에의해 증가한 에스피1등이 mitA를 억제. 이러한 결과들을 통해서 SP1이 암 증식 chip assay 4OHE는 EMT 촉진된다. 억제 - Mithramycin A 촉진 - DMBA, CYP1B1, SP1, 4OHE Matrigel, migration -&gt; migration, invasion 1B1에 의해 대사되는 irinotecan - 알수가 없다. Tumor 조직을 갖고 enzyme activity 측정전에. active metabolism 2D6는 steroid 7.2.4 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology Speaker: Kyu-pyo Kim (University of Ulsan College of Medicine, KOREA) effects are not immediate / severe adverse effects / narrow therapeutic window UGT1A1 genotypes - different enzyme activities , Irinotecan Irinotecan -&gt; practical decision making - not reached. genotype information - strong enough? neutropenia, diarrhea mutations are abundant - mutational loading (high- melanoma, lung sq cel carcinoma) Point mutations, copy # variation -&gt; omics + NGS -&gt; clinical interpretation -&gt; clinical decision making Ca Cancer J Clin 2016 - 1 month TIME IS IMPORTANT FOR PATIENTS. Issues : Forces or hurdles - COSTS - volume of patients/turnaround time/Central testing/Quality control NCI-Match - somatic mutation - Oncomine Comprehensive Assay Gene List - How to report??? KRAS A146 mutation in CRC -&gt; CTX guideline - clinical trial CPCM - KCSG 11th methodology - Transition : from research to practice - CLIA (23andMe) NGS 임상검사실 인증제도 추진중임. Summary - abundance of information is helpting us there are many hurdles multi-disciplinary efforts are needed. "],
["translation-and-convergence-for-future-medicine.html", "Chapter 8 “Translation and Convergence for Future Medicine” 8.1 Plenary Session II “의료기술및 R&amp;D 변화의최신동향” 8.2 Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]", " Chapter 8 “Translation and Convergence for Future Medicine” 미래 의학을 위한 중개 및 융합연구 Asan International Medical Symposium 2016 Innovative Future for Medical Science &amp; Technology - 2016년 6월 17일 (금) 서울아산병원 동관 6층 대강당 외 AIMS 8.1 Plenary Session II “의료기술및 R&amp;D 변화의최신동향” Chairperson :김청수(서울아산병원비뇨기과교수) 8.1.1 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용 Speaker: David W. Bates (Harvard University, Brigham and Women’s Hospital, USA) Rising costs Moneyball, Boston red sox, walmart, watson Big data 1M - 1giga(human genome) - 1 peta EHR, Genetics, Diagnostics, Mobile devices, Meaningful Use - EHR - growing. https://www.healthit.gov/providers-professionals/meaningful-use-definition-objectives https://healthit.gov Big data concepts Validation is important! Big data and research - Brigham and Women’s - Pathology ePath, Immunology Big data Genomic platform Essential for future approach RPDR - New entity at partners healthcare = CMS, biobank, survey data, imaging, notes repo Big data in clinical care 5% patients ~ 50% cost iCMP claims-based approach - 3000 patients multiple parameters - wearable devices - continuous supervision on general care floors Adverse events PCORnet - not popular New Sources - the trajectory of mobile apps Literature Review - 7301 titles and abstracts App Review - iTunes, Google Play -&gt; possibly useful 16 Professional Society Review - Ginger.io https://ginger.io/ to drive better health outcomes through the use of passive mobile data and behavioral analytics. !!! Example projects - Predictive Modeling What we need to do all these Analytics tools, repo, data warehouse, epic reporting (Clarity reporting database) Clinical data - ubiquitous !!!!Novel sources are most likely to provide marginal improvement - social, mobile!!!! Predictions / Implications Transformative as the internet Killer app - Google Maps 8.1.1.1 Questions 김규표 교수님 - Social media and health care 김청수 교수님 - Government and insurance - reasonably difficult to acquire - costly. 8.1.2 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로 Sachdev Sidhu (University of Toronto, Canada) The Donnelly Centre - From systems biology to systematic treatment Therapeutic antibody revolution - highly versatile, numorous diseases Ab-durg conjugates, fragment, bispecific, engineered cells Targeting cancer with antibodies !!! problem - small populations - boutique treatment!!! In vitro protein evolution Affinity, specificity enhanced Antibody molecules binding site of Ab highly optimized - automatic mutation of binding site Toronto Synthetic Antibody Library - highly diverse - Herceptin PHAGE - Genentech only changed the function, not others Functional genomics - Large-scale, industry-quality Ab generation - Preclinical biology | The middle was not quite available but now it’s doable. Cancer Antibody TRAC antibodies - bacerial pathogens High yield and high affinity Fabs from naive library - 1394 total against 80 targets http://sites.utoronto.ca/sidhulab/about.html natural - synthetic Ab - synthetic proteins - synthesizable proteins D-protein therapeutics.- samll proteins synthesized entirely rom D-amino acids, Ab like affinity, specificity and stability, in vitro d-protein advantages - longer circulating HL than L-proteins - less immunogenicity - ersistant to metabolism in plasma 8.2 Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당] 15:20 ~ 18:00 8.2.1 Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA) Data warehouse : integrates data from multiple sources - i2b2 | ABLE | OHDSI who entered the data? Wrong input to public repo (DKA for 2 years!) Data quality Raynaud’s syndrome - Omega3 (Failure) 8.2.2 Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA) 8 seconds = Concentration time Analytics Convergence Zone - Clinical data, Geo/Social/Environmental data/Claims&amp;Cost Data/Pharma&amp;Life Sience Data, Patient &amp; Citizen Data https://powerbi.microsoft.com/ko-kr/ !!!!! 반드시 사용해 볼것. 좋은 Visualization. http://www.ciokorea.com/news/29118 8.2.3 Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법 speaker: 김 선 (서울대학교 생물정보연구소) https://sites.google.com/site/biohealthinformaticslab/sun-kim http://bioinfo.snu.ac.kr/main/index.php DNA, RNA, Protein이 중요 - Somatic mutation뿐만 아니라 Transcriptome (RNA-sequencing data) 싸고 쉽다. 그에 비해 Underestimated되어 있다. Breast cancer 가장 잘 알려진 암종. 21-gene Oncotype DX !!! http://www.oncotypedx.com/ PAM50 - Prediction analysis of microarray by 50 gene classifier !!! - Survival 예측하는 Gold-standard Transcriptome Data analysis http://prosigna.com/x-us/overview/ Pathway (context) analysis는 과연 informative한가? A Critical Evaluation of Network and Pathway-Based Classifiers for Outcome Prediction in Breast Cancer (PLoS One 2012) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034796 50개를 랜덤하게 취해도 유의미하게 나왔다. 아무거나 취해도 유의미하게 만들 수 있다. (Negative result!) “Based on these results there is currently no reason to prefer prognostic classifiers based on composite features over single genes classifiers for predicting outcome in breast cancer.” 따라서 50개를 정할 때 기능적인 면을 고려해야 한다. PPI-based Pathway Decomposition !!! - 우리의 분류를 기반으로 Survival plot를 그리면 확연한 차이가 난다. Decomposed pathway and its activity measurement Using RNA-sequencing data 이러한 알고리듬으로 RNA-sequencing data 분석 (1138개의 sample을 사용) TCGA data (Breast Cancer) 기본적으로 information theory를 응용한 것이다. Subtype과 발현량의 ranking에 따라 score를 매긴 후 distinguishing할 수 있다. 클래스마다 차이가 확연한 Subnetwork A는 좋은 모델 클래스마다 차이가 없으면 Subnetwork C는 나쁜 모델. 우리는 좋은 모델을 택해야 한다. Top10 Regulated pathways by TF/miRNA mir-30a (basal cell cycle activation) -&gt; mir-149, let-7b, mir-30a Sub-network mining approach Experimental validation requires collaborators who enjoy new approaches. 혹시 talk를 들으시고 관심있으면 Contact. http://aims.amc.seoul.kr/asan/imageDown/homebuilder/20160527?fileName=Scientific-Program-kor.jpg http://www.amc.seoul.kr/asan/academy/event/eventDetail.do?eventId=572 http://aims.amc.seoul.kr/asan/depts/aims/E/deptMain.do "],
["acrep.html", "Chapter 9 ACREP 9.1 Observational Study 9.2 Observational Study의 Pitfall 및 이를 극복하기 위한 방법 9.3 Diagnostic test &amp; Biomarker Study 9.4 2차 자료원을 이용한 역학 연구군 9.5 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법 9.6 Web-r.org", " Chapter 9 ACREP 9.1 Observational Study Speaker 이무송 9.1.1 Contents Cohort study RR \\[ \\frac{\\frac{a}{a+b}}{\\frac{c}{c+d}} \\] 단점 - F/U loss, 재발에 대해서 연구 어렵다. 연구 대상 수 산출 방법 - Nomogram, 수식적용, 컴퓨터 PASS 2016 PCORI.org - conduct of Registry Cohort는 F/U을 전제로 해서 한다. Retrospective Chart-review 9.2 Observational Study의 Pitfall 및 이를 극복하기 위한 방법 Speaker: 임영석 교수님 9.2.1 Experimental study? Yes 9.2.1.1 Randomized design? (interventional)- No NR CLINICAL trial Time series PHASE 1 9.2.1.2 Randomized design? (interventional)- Yes Clinical Trial Community Trial Crossover design 9.2.2 Experimental study? No 9.2.2.1 Comparison group? No = Observational study Prevalence / incidence, time trend, case series, case reoprt 9.2.2.2 Comparison group? Yes = Analytical study Cohort study, case-control study, cross-sectional study, ecologic study, PMS 두군을 비교하는가 안하는가가 중요한 기준이 된다. 9.2.3 Contents research question -(design)- study plan -(implement)- actual study findings in the study -(infer)- truth in the study -(infer)- truth in the universe 위암, 대장, 폐암 - post op outcome을 통채로 비교하면 안된다. internal validity &amp; external validity(generalization) PICO anatomy ##### patient/population/problemn Intervention Comparison Outcome Gold standard of clinical studies - RCT Sample - randomization (Treated / Control) Research question - interesting, important, critical Good research question - FINER - Feasible, Interesting, Novel, Ethical, Relevant Feasible / Ethical / Relevant 가장 중요한 면 Prospective Cohort Study - Case-control study - 뒤로 간다. 병원에서 case-control 하는 경우는 사망여부. Outcome인 경우가 많다. disease있고 없고가 아니라. 재발에 대한 - 환자군/대조군을 모아서. 그럼 어떻게 대조군 설정한건가?? 이런 것을 정할때 bias가 많이 발생하게 된다. Historical cohort - Cohort assembled-(f/u)-&gt;Outcome 2000-2010 HCC 초치료 근치적 수술적 절제술 받은 환자들의 명단을 확보. ITT analysis할때 반드시 필요하다. 5년 이상 관찰한 것이 있어. Mimic those of clinical trials Internal validity를 높여야 한다. restricted cohort / NEJM 2000;342:1887 IIT 분석을 해라. Chance(Random Error) vs Bias(Systematic Error) association / cause를 비교해야. Confounder biasd와는 좀 다르다. 미리 의식하고 물어보기 전엔 절대 알수 없다. 미리 질환에 대해 잘 알고있는 연구자여야만 찾을 수 있다. Example : smoking - alcohol - heart disease What is the effect of long-term tx(&gt;5y) with a potent oral antiviral agent(entecavir)(I) in patients with chronic hep B(P) FDA, 식약처는 Surrogate marker를 가지고 허가를 내준다. (조직학적 개선,) - 이것과 환자의 outcome을 정말로 개선시키는건가? 이건 observational study에서만 찾을 수 있다. historical cohort Zero time No treatment control Endpoint ascertainment - 재발이 문제가 된다. 무엇으로 재발을 판정할 것인가? MR? CT? 검사간격을 얼마로 했니? 누구도 시비 못할 것으로 outcome measure하는 것이 좋다. (예를 들어 사망의 경우) PP vs ITT ITT - which treatment option is best at the time decision must be made? - FDA에서 ITT만 인정을 한다. Explanatory Multivariable Cox PH Analysis - (Event 수를 적어야 한다.) Univariate analysis만으로는 부족. Multivariate analysis - Propensity score - SPSS로 가능. 양군간 matching - 쌍을 갖춘다. 같은 수로 나온다. 이때는 univariate할 수 있다. “consistently observed by unadjusted.” - obs study는 의심을 많이 받기 때문에. 이런 분석을 하는 것이 좋다. Gadoxetic - liver specific contrast agent 2647patients-&gt;700명 수술 가능. - surrogate marker - CT에서 못본걸 MR에서 찾았다. | Cost-effectiveness - 무조건 survival. Propensity matching - Inverse Probability Weighing (IPTW) Unadjsted mutivariable IPTW Propensity 제목의 중요성. JCO (IF 21) - Hepatology (IF 11.7) - Gut (IF 14.921) (early rejection so far) - GE (IF 18.187) (accepted with more general terms in the title) 9.2.4 Conclusion mimic as closely as possible in RCT 9.3 Diagnostic test &amp; Biomarker Study Speaker: 박성호 - 영상의학과 9.3.1 Contents - Diagnostic test DTA sutdy Prevalence낮으면 횡으로 본다. Predictive Value - Prevalence에 영향을 받는다. Pre올라가면 PPV올라가. NPV낮아져. odds ratio - prevalence에 영향을 안받는다. intrinsic parameter로 많이 씀. case-control study vs cross-sectional study [옛날 용어] Cochrane - case-control type accuracy study vs cohort type accuracy study NECA - diagnostic case-control study vs diagnostic cohort study Area under ROC curve - C statistics Youden index - sens spec 더해서 빼기 1 Youden J statistic Least Euclidean distance from (0,1) 거리가 최소되는 점. - 쉬운개념 diagnostic accuracy - 시각적으로 어떻게 구성하는지가 중요함. McNemar test Comparing two proportions (2x2) - unpaired(fisher,Chi2), paired (McNemar) 9.3.2 Contents - Biomarker Biomarker Classifier / Prognostic / Predictive / Monitoring Petal et al. MRI-detected tumor response for locally advanced rectal cancer predicts survival outcomes Machtay et al. Prediction of survival Prospective S III lung cancer eligible for CCRT Endpoint : overall survival SUV Hylton et al. Prospective Index: functional tumor volume measured with pre-surgery breast MRI Comparator: post-surgical pathologic complete response(PCR) Modified C-statistics(ROC) - diagnosis는 있다 없다로 나온다. survival은 time to event - 각각의 time point마다 diagnosis 유사한 통계량이 나와서 그걸 summation Studies of predictive accuracy Two approaches - Time-to-event / event by a fixed time Event by a fixed time - Sn Sp ROC - Accuracy study와 유사한 것으로 된다. 더 impact있는 것. - randomization을 테스트 후에 할 것인가 아니면 전에 할 것인가? 전에 하는 것이 더 임팩트 있다. 왜냐하면 테스트(+)이면 치료 들어가는 경우가 많기 때문이다. 후자에 해당하는 (더 임팩트있는) 스터디의 예. Monitoring biomarker Correlation between x and y / delta x and delta y Delta를 보는 것이 중요하다. 9.4 2차 자료원을 이용한 역학 연구군 Speaker: 예방의학교실/의학통계학과 김화정 NEJM 2006, BMI and mortality 이차자료원 : 특정한 연구목적으로 수집되지 않은 자료 공공데이터 - 정부 국건영 심평원 자료 - 생각보다 manage하기 쉽지 않다. HIRA DB - 건강보험청구자료 NHISS 국민건강보험자료 공유서비스 보건의료 연구에 활용되는 공공데이터 장점 : 대규모자료, 장기간 추적관찰. 시간과 비용 절약 한국형 - outcomes Research NECA에서 자료를 연계해 주겠다 라고 했으나.. 진전이 크지 않음 보건의료 빅데이터 개방시스템 - 공공데이터 명세서 일반내역 테이블 2차자료의 분석은 case-control의 기준 정하기가 어렵다. 금방 분석이 되기 힘듬. Crossvalidation 반드시 해야함. 과제신청 - 연구원등록 : 정부3.0에서 검토 자세히 하게됨. SAS/R 프로그램. 단점 - 5년간의 자료. F/U보기가 힘들어. 진단명의 정확도 문제 - 70%. 에러의 숫자가 클 수 있음. 의학통계학과 공공데이터 연구지원 #4639 - 상담, 공공데이터 이용신청, 자료확보, 자료분석, 결과검토 NHISS 표본연구 Dramatic decrease in FQ in the pediatric population case crossover design indication bias - causality - association. confounding by indication 9.5 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법 Clinical prediction model Framingham risk score JAMA - moving from clinical trials to precision Medicine, 2016 Apr 26 DAPT Trial Risk for advanced neoplasia and likelihood ratios in each risk group within derivation and validation sets Derivation and validation of a scoring system to stratify the risk of advanced colorectal neoplasia in asymptomatic adults 분자:질병있는 / 분모:질병없는 - likelihood ratio Assumptions for model development - linear regression, Cox proportional hazard regression(Proportionality of hazard ### This should be confirmed.) linear reg logi reg Cox reg Overall perf R2 Nagelkerke r2, brir the same discrimination ability C concordance stat(AUC) Harell C stat, time-dependent AUC Calibratrion Calibration plot, slope the same+hosmer-lemeshow the same C-index 를 사용하여 분석 가능함. C = number of concordant pairs + 0.5/~~ 새로운 통계 지표. 2가지. NRI - net eclassification improvement Korean J Radiol 2016;17(3);339-350 -&gt; predicted probability - 사망할 확률을 계산할 수 있음. Framingham그룹에서 발표됨 2008 통계 저널에 9.6 Web-r.org Speaker: 문건웅 가톨릭대학교 성빈센트병원 심장내과 9.6.1 Contents web-r.org 로지스틱 리그레션 - 반응(종속)변수 - 설명변수 . 단변량 분석 먼저 나와 univariate logistic regression 다변량 분석. 생존분석 - 로지스틱 회귀분석과 비슷한것임. - 다른 것은 시간개념이 들어있는 것임. 얼마 있다가 돌아가셨는지 알 수 있음. KM 분석. cutpoint결정해줌. 나무분석 - 생존 나무 분석. 진단통계 "],
["prism-2016.html", "Chapter 10 Prism 2016 10.1 Morning Session 10.2 Afternoon Session", " Chapter 10 Prism 2016 10.1 Morning Session 10.1.1 Lim Covariate model 10.1.1.1 Ischemic stroke Primary endpoint time-to-primary endpoint (time-to-event) late recurrence, DM Secondary endpoint late recurrence 통상적인 VPC - K-M plots Modeling and simulation analysis of the relationship between lesion recurrence on brain images and clinical recurrence in patients with ischemic stroke1 [1] 10.1.1.2 MR image -&gt; 예후 예측 mRS (modified Rankin Scale) 응급실에 왔을때 DM - NIH scale 3D Plot 광학영상 - preclinical 에서 부터 NONMEM을 사용해서 10.1.2 FDA - Lee http://www.dailypharm.com/News/202010 Joga Gobburu - 인도사람 Yaning Wang - deputy director Vikram Sinha math molecular biology - impressive - reviewer Office of CP - 7개 division, 1~5 clinical division- 질환별로 - align (DCP) PM(떠오르는 학문) PG division 10.1.3 Pfizer 파리바? 크루시파이? - Metz Karlsson과는 아니고.. 파일러비시니? UW - metrician -&gt; 임상약리에서 뽑았다. (파리바) 피터 뮬리건? &lt;-&gt; 아만티아(놀려고 함..) 밥 파월 = 임동석 선생님 10.2 Afternoon Session 2016.07.12 10.2.1 Kim Modeling Buzz words M&amp;S SP&amp;PMx - MBDD - MIDD - MID3 (Drug discovery and deveopment) Lean, apply and confirm Case I : use of pk modeling in pre-cilnical stage NOAEL : Rat 250mg, dog 500mg/kg Target exposure Questions - have we selected right starting dose? - FDA MRSD (FDA guidance) - following actions were taken Proposed FTiH dose were 50mg, 100mg~1200mga Dose 5-200mg MABEL, maybe a challenge but doable with lower s NOAEL - MABEL - allometry = we should use all of these. Case II : Use of PK in FTiH study Dose Escalation Stage Unexpectedly longer half life (x5) everything is impacted. POC study Questions arose Emax model -&gt; nice when it’s adhered to the predicted. New formulation development Case III : Use of PK in FTiH / BIAL lab, BIOTRIAL research site in Rennes, France BIA-102474-101 study design SAD 8 cohorts SAD -&gt; Food effect -&gt; MAD What caused these events - threshold, off-target pharmacology, FAAH inhibition TSSC report -&gt; Interesting observation related to PK - elimination HL of BIA is gradually extended. Non-proportionality begins. Non-proportionality - SAE probability Emax model - 80% !!! 50mg QD Recommendation : use of sentinel London incident, early human (Prediction) Summary - PK, PK/PD modeling and simulation is essential Questions - 2010 MAD -&gt; okay 505 MAD -&gt; not okay, why? - Eye drop -&gt; allometry experience? 10.2.2 Strategic application of PM in global drug development: Experience from Hanmi Speaker: Lee Young Mi, Hanmi Why do we need PM? - biologically effective dose, earlier translational risk assessment, safety margin(systemic and quantitative translation of animal models to clinic), Pre-clinical modeling to guide clinical dosing, enhancing early stage decision-making, evidence-based decision making and accelerate drug approval Systemic and quantitative translational research. PK&amp;PD -&gt; target occupancy, mechanism Human PK projections - LAPSCOVERY development strategy DRUG+AGLYCOSYLATED FC - Flexible linker Longer duration - once weekly, once monthly -&gt; FcRn mediated endothelium recycling / avoiding renal filtration!!!!! - Kidney failure patient can receive the LAPSCOVERY drug. Long-acting protein/peptide GLP1, insulin, somatostatin : peptide Protein : hGH, IFNa, mG-CSF Exendin-4 analog, IFNa -&gt; protein LAPSInsulin A (analog of insuling) -&gt; longer HL -&gt; human serum conc vs time profile Case 2. Targeted therapy &amp; surrogate PD marker It is important to select PD marker!!! Some cancer - hard to choose PD marker. (Eg. Lung ca) phosphoEGFR - OLITA (olmutinib) - breakthrough theray designation (FDA) by US FDA - phase II BTD -&gt; modeling when the n= increased??? -&gt; licensed out to Behringer Ingelheim Exposure-Response : PK-PD Recommended dose selection - CRITICAL!!! PK-PD Xenograft Targeted therapy &amp; biomarkers - BRAF/KRASmut inhibitor Next gen RAF inhibitor(PanRAF) (&lt;-&gt; Classical RAF inhibitor = rebound MAPK reacitivation) Methods difference (pMEK), (pERK) -&gt; aided dose seletion (lower exposure and the same PD marker) HM95573 and Cobimetinib in MAPK activated HCC cell lines combination -&gt; can lower dose 10.2.3 MBDD Speaker: Lim MBDD (Learn &amp; confirm cycle) course run Information management tool = Modeling Quantitative information (GO/NO-GO decision) Various and diverse information Quick win, fast fail - PK/PD modeling and simulation Abundance of drug discovery - preclinical development (Mechanism-based biomarker, imaging biomarker) - accelerated PoC (IIb/IIa) - confirmation, dose finding System-specific parameters, drug-specific parameters, structural model Extrapolation Quantify the exposure in remote and/or inaccessible Allometry vs PBPK assumes that the nly diff between human and the other mammals is size = imprecise, mono-exponential elimination DHP107 - IV paclitaxel 480mg/m2 was the most common MTD(Maximal Tolerability Dose) in virtual phase 1 trial for DHP107 Case II - Ticagrelor PD ticagrelor and AR-C124910XX Maximal platelet aggregation Case III - Early characterization of an antibiotics using bacterial time kill assays and human PK study Preclinical PD + Human PK =&gt; Predict human PD Monte-Carlo simulation using PK/PD model Case IV - integrative PK/PD Model 16182HanLimPyung441) - MFDS Integrative, mechanistic PK/PD model Tumor size Questions - NONMEM -&gt; PBPK? ADAPT?(Program?) - THETA, ETA (60-70) Generally 40 10.2.4 Pharmacometric information in drug label Speaker : Bae Ocaliva (obeticholic acid tablets) oral use | initial U.S. Approval 2016.05.27 - FXR agonist - Tx of PBC - Omega matrix -&gt; POPPK analysis NUPLAZID (pimavanserin) Parkinson’s ds psychosis POP modeling 구체적목적 fixed effects covariate 찾는다 interintra subject random variability의 크기를 평가 개인별 pk,pd 농도, 폭로, 반응/효과, 유해반응 simulation하기 위한 모형을 구축 Total variability Fixed portion + random portion fixed effect = explainable Eta (interindividual (random) variability) NONMEM F = function of (theta, , covariates) # Fixed Y = function of (F, epsilon) # eta=0(무시)하면서 예측한경우 = Typical prediction theta = constant, nu~MVN(0,omega), eta~MVN(0, sigma) 확률변수 Covariates - usually dose, time, demographics and other measurement Epsilon = express homoscedastic, proportional, exponential or combined errors Dose,time = covariate (statistics) Eta - Realized Eta = 0이 아닌 숫자화된 Eta (inter individual)고려해서 한거 - F:IPRE F:PRED(Typical prediction) Population Concept Eur J Pediatr(2015) 174:1671-8 Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation - [2] CL, Vd(실제론 둘이 연관이 있다.) -&gt; Correlation을 유지한 채로 sampling 되도록. MVN Pharmacometric Review : pop PK-PD model Visual Predicted Check Prediction band The fast-growing consumption of caffeinated energy drinks (CEDs) is linked to increasing reports of caffeine intoxication in adolescents. There is limited data available regarding plasma caffeine concentrations in this population after CED intake and the potential implications for caffeine-related toxicity. This study was an in silico population pharmacokinetic analysis of caffeine. Population pharmacokinetic model of oral caffeine was derived from a previous study of healthy male volunteers. Maximal plasma caffeine concentration (C max) profiles following ingestion of one or two servings of popular CEDs were predicted using Monte Carlo simulation and available population body weight data of 10–15-year-old Korean adolescents. Caffeine C max values were positively correlated with the amount of caffeine ingested in CEDs and negatively correlated with body weight. The median (range) C max profiles varied from a low of 1.2 (0.5–2.6) mg/L to a concentration that is potentially associated with harmful caffeine-related effects of 25.4 (8.1–55.6) mg/L. A subgroup of female 10–11-year-old subjects exhibited the highest caffeine exposure profiles. Conclusion: These data indicate that CED ingestion can increase the risk of serious caffeine intoxication in young adolescents, particularly those with low body mass. 10.2.5 Pharmacometrics in Dose Optimization Speaker : Jee Eun Lee, FDA Interindividual variability (PD, PK) Secukinumab (Cosentyx) - target population https://en.wikipedia.org/wiki/Secukinumab (Novartis) Example of dose optimization IL-17(A) - Etanercept, infliximab, adalimumab(humira, shallow), ustekinumab = biologics 몸무게 크면 IgA, 4 Phase III, (2 of them were pivotal study) PMC - post marketing commitment the higher conc. =&gt; the higher incidence of infections (tolerable) Edoxaban (흥미로운 약물) NOAC - New Oral Anti-coagulants (4th) 1st rivaroxaban, 2nd dabigatran(issue-EMA), 3rd apixaban Ace Meeting? Normal - Mild - Moderate Exposure - response relationships (Efficacy-Stroke, safety-bleeding) Benefir-risk relationship is not novel. (Dabigatran: RE-LY trial) exposure-response relationship PK matching. ## Writing 2 Bibtex entries ... ## OK ## Results written to file &#39;References.bib&#39; Reference "],
["MFDS.html", "Chapter 11 MFDS-Asan Joint Symposium on Rare Diseases 2016 11.1 Session 1 Rare diseases in Korea : Status &amp; Research experiences 11.2 Session 2 Global regulatory experiences in orphan drug development 11.3 Session 3 Lessons and learned : R&amp;D for rare disease 11.4 Session 4 Asan initia tives for rare disease", " Chapter 11 MFDS-Asan Joint Symposium on Rare Diseases 2016 Accelerating Research and Development of Orphan Drugs for Rare Diseases 식품의약품안전처-서울아산병원 임상시험글로벌선도센터 공동 주관 심포지엄 11.1 Session 1 Rare diseases in Korea : Status &amp; Research experiences 11.1.1 National support for rare disease : Current status and future prospects Speaker : Hyun-Young Park, M.D., Ph.D. Centers for Disease Control and Prevention Orphan disease Disease criteria : EU 5/10000, US &lt;200k, japan &lt;50k, WHO &lt;6.5-10/10k, 유병인구 &lt;20k 희귀성 : market failure 2012 유전자 진단지원, 2016 희귀질환 종합대책 희귀 난치성질환 전문정보 - helpline IRDiRC 정부지원사업의 문제점 11.1.2 Translational research for drug development : Historical perspective Speaker : Seung-Eun Choi, M.D., Ph.D. Ministry of Food and Drug Safety TM - History not so long 2004 T1(testing in humans), T2 11.2 Session 2 Global regulatory experiences in orphan drug development 11.2.1 Considerations for drug development for rare diseases : Cases of inborn errors of metabolism Speaker: In Sook Kim, Ph.D. FDA Office of Clinical Pharmacology Beginning with the goal in mind 45 NME/New BLA in 2015 Novel Drug Approval for rare diseases 2010-2015, 77 novel drugs for rare (37 cancer, 10 inborn e of metabolism) Rare disease (Orphan disease) - less than 200k ~500 rare disease have approved drugs. / ~7000 rare disease Goals: safe and efficacious drug uncertainty를 줄이고, evidence of efficacy and safety Challenging: Limited clinical experiences, Lakc of understanding of natural history of the disease - limited opportunities for learning Ivacaftor: CFTR protein - for G551D(Defective CFTR protein), hard to apply Phase II Trial Phase 2 Trial - 39 patients PD parameters: sweat Cl, Nose potential difference, Lung function: FEV1 NEJM Eliglustat (Cerdelga®) glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test Metabolized by CYP2D6, CYP3A4 Simulation and Modeling EM, systemic exposure at SS is 7-9 fold higher in poor metabolizer PBPK analysis - CYP2D6, CYP3A4 inhibitor 동시에 넣었을때 24배 증가 prediction Contraindication! Risk management에서 중요함! Sebelipase alfa (Kanuma®) 2 Pivotal studies (Infantile-onset(Wolman ds), Late-onset(Cholesteryl ester storage ds)) FDA-APPROVED TREATMENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) Webpage2 Opportunities for innovation 11.2.2 Role of pharmacometrics in the development of orphan drugs Speaker: Jee Eun Lee, Ph.D. FDA Orphan drug Act NORD (National Organization for Rare Disorders) Orphan vs non-orphan (# of CT 2.8 vs 3.5) Pharmacometric analysis in 26% and 84% were pivotal for approval and labeling decisions, respectively. Oncology에서는 body weight. drug &amp; surface의 관계가 있다. Adalimumab in pediatric CD CDAI vs PCDAI J.Lee Digestive Disease Week, 2016 Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling [???]3 11.3 Session 3 Lessons and learned : R&amp;D for rare disease 11.3.1 Lessons from an orphan drug development (I) Speaker: Marcus Martin Klein, JPAC Medical Head SANOFI GENZYME Gaucher ds. 11.3.2 Lessons from an orphan drug development (II) Speaker: June Young Park, Vice President ISU ABXIS 혈우병 치료제 11.3.3 Case studies on inflammatory bowel disease Asan Medical Center Speaker: Byong Duk Ye, M.D., Ph.D. Asan Medical Center 젊을때 발병해서 평생 지속되는 안좋은 특성 원인 잘 몰라 Genetic predisposition, gut microbiota (dysbiosis) Korean GWAS Gut 양석균 11.3.4 Case studies on drug targets in rare &amp; ultra-rare genetic disorders Speaker: Yoo Han-wook, M.D., Ph.D. Asan Medical Center Disease-driven vs Drug driven transformative drugs of past 25 years ultra-rare genetic disorders e-patient movement UDP, rare disease consortium Palallel mover 11.4 Session 4 Asan initia tives for rare disease 11.4.1 Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience) Speaker: Kyu-pyo Kim, M.D., Ph.D. Asan Medical Center Disease Registry : REDCap, Research Electronic Data Capture (eCRF) CDMSs ABLE (clinical data) CRF Review redcap.amc.seoul.kr cancer, ARDS, ILD, ARCD Longitudinal registries that self-update can be important to investigators Identifying the population and individual may benefit 11.4.2 Align commercial and development team to forecast success through “PRISM” Speaker: Young-Kwang Yoon, Ph.D. Asan Medical Center 11.4.3 Knowledge and perceptions of clinical research of patients suffering from rare diseases Speaker : So Young Park, M.D. Asan Medical Center Chapter 17:15 ~ 17:25 (’10) Q &amp; A 17:25 ~ 17:30 (’05) Wrap-up http://news.alexionpharma.com/press-release/product-news/fda-approves-kanuma-sebelipase-alfa-treatment-patients-lysosomal-acid-lip↩ http://dmd.aspetjournals.org/content/44/7/924.long↩ "],
["toxicology-2016.html", "Chapter 12 Toxicology 2016 12.1 Key links 12.2 Session I 2016-08-22 12.3 Session II 2016-08-23", " Chapter 12 Toxicology 2016 author: 한성필 date: 2016-08-22 ~ 2016-08-23 venue: 숙명여자대학교 백주년기념관 2층 컨벤션 센터 12.1 Key links 한국독성학회 Benchmarks in Toxicology ICH guideline 의약품의 임상시험 수행과 품목허가를 위한 비임상시험가이드라인 생물의약품 비임상시험 가이드라인(2014) 12.2 Session I 2016-08-22 12.2.1 독성학 개론 및 발현기전 !!!! 홍진태: 충북대학교 독성학에 많은 분야가 있다. (규제독성학 : 가습기살균제) Toxin vs Toxicant man-made Toxicity, Hazard(상태), Safety(risk의 반대 개념), Risk(probability), Risk Assessment Idiosyncratic reaction, delayed toxicity(중국에서 온 조류, 잔류성 농약 먹고 우리나라 와서 독성) 화학적 상호작용 - Additive, synergistic, potentiation, antagonism 용량-반응관계 - 유해성 평가에서 중요한 factor - Dose-response - sigmoid하게 나타난다. 그룹별로 나타난걸 Quantal이라고 한다. 직선형으로 표현할 수도 있다. 기울기도 봐야 한다. B는 다루기가 힘든 약 (Steep) LD50는 같을 지라도 주의해야 한다. 효력Potency vs 효능efficacy Morphine / aspirin Therapeutic index - LD50/ED50 Margin of safety - LD1/ED99 Margin of exposure = exposure level / TD10 Subchronic / chronic dose response - Liver necrosis - LOAEL NOAEL(No observed AE level) ADI, RfD, TDI 만성 노출에 대한 허용치를 결정하는 전형적인 시발점 Benchmark dose (모델링을 사용해서 결정) threshold 독성 영향 인자 selective 생체내 전환 malathion : 사람 vs 곤충(곤충에만 축적) 빈도, 농도, 용량, 부위, 경로, 시각(chronopharmacology)-마우스 KCN치사율에 대한 circadian susceptibility(심박동 낮고 안정화된 아침에 투약) 내인성 인자: 종, 성별, 연령, 체중/신체구성 동물 독성 연구 - 동물에서의 노출과 영향을 연구 TCDD에 노출된 rat의 종양 발생 독성 시험의 유형 - 단회, 반복 투여 독성 시험, 유전 독성, 면역 독성, 발암성 시험, 국소 독성 시험, 메커니즘 연구, OMICS 활용 독성 Mechanism of Toxicity Delivery, Reaction, Toxicity, Repair Exposure of Toxic chemicals -&gt; Ultimate toxicant + Target molecule Type of Ultimate toxicants and their sources 대사체가 xenobiotic toxicant Reactive oxygen or nitrogen species as ultimate toxicants Endogenous compounds as ultimate toxicants (lipid - peroxidation, Bilirubin) Distribution (Specialized transport - ochratoxi, MPTP into DA neuron Accumulation (Away from the target - MDR) Excretion vs reabsorption Excretion (volatile, non-volatile) reabsorption (tubular fluid reabsorption, carrier in kidney, intestinal lumen) - 우리 몸에선 약산, 약알칼리, 중성의 약물 - PH가 중요하다. PKA salicylic acid (알칼리에서 reabs 감소), morphine(산성에서 reabs 감소) Toxication vs detoxication electrophiles : nonionic, cationic nucleophiles : amygdalin -&gt; cyanide free radical formation Xenobiotics -&gt; super oxide P450 reductase PQ, DR, NF 전자를 하나 받아서 reduct한 효소로 바뀐게 산소와 반응해서 free radical 만들게 된다. reduce된다. (전자빠지면서) reactant가 된다. Endogenous sources of O2 One electron oxidation by peroxidases or P450 superoxide anion radical toxication Detoxication of free radical SOD, Catalase, GPX, HO(ineffective), ONOO- : free radical scavenge Reaction (반응 - ultimate toxicants-target) Target molecule(DNA, ptn, memb lipid, coenzyme) Types of reactions Non-covalent : hydrogen, memb receptor, PKC, acridine Covalent hydrogen abstract : R-SH -&gt; RS* CH3 -&gt; CH2*, DNA -&gt; C4 radical, lipid - lipid peroxidation effects of toicants on targets dysfunction of target (mimicking endogenous ligands, morphine(opiate receptor), protein function impairment destruction of targets cellular dysfunction TK, GPCR, Hormone receptor excitable cell dysfunction - alternation of signal cocaine (adrenergic vasoconstriction) Toxic alternation Mechanism of apoptosis + ATP depletion, Ca increase, overpopulation of ROS(PARP increase - DNA injury)) Protein repair(ubi, autophagy) 12.2.2 면역독성 ! 최경철: 충북대학교 Introduction to WBC Introduction to lymphoid organs Sentinal cells - MQ, DC, Mast cells Structure of LN - B cell은 cortex에 존재함. Ag 만나 proliferation -&gt; class switching (항체를 만든다, cortex에서) Structure of spleen - Red pulp (RBC), white pulp(WBC) Hypersensitivity reactions (과민반응) - I, II, III(혈관염), IV Quiz: Acquired immunity - B cells BCR -&gt; antibody Helper T -&gt; CD4 major 2차면역기관 - A,E ICH.org - E2B, CTD, MedDra ICH S6 guideline - TDAR, phenotyping 등을 해야 한다. S8 guideline (immunotoxicology studies) - STS (standard toxicology study) -&gt; factors to consider in the eval of potential immunotoxicity Hapten (low MW, unpredictable, immunogenecity) Introduction to antibody Type II, III - no standard, non-clinical test (Coombs test) murine LLNA (local LN assay) - thymidine -&gt; DNA 합성시 incorporation - beta counter로 잴 수 있다. Quiz: 면역독성 카테고리 포함 안되는것? - Abnormal APC (IS, IG, HS, AI) 면역조직 아닌거? - Thyroid gl. Type IV 과민증 (Buehler , maximization, optimization) 아닌것은? Passive cutaneous anaphyl, maxi test - 동물은? guinea pig Autoimmunity 비이상적인 현상 ImmunoSuppression 아닌 것은? myelosupp, 면역 기관 위축, serum globulin증가(wrong!), 감염증가 12.2.3 독성시험과 통계 !! 이영주: 경희대학교 기술통계, 추측통계 대표값 + 산포도 산술평균 - 극단치에 영향을 많이 받음, 명목변수, 순위변수에는 부적합(예-암1기, 2기), skewed distribution에는 부적합 기하평균 - 분포가 한쪽으로 치우쳐 로그변환하여 사용하는 경우(Cmax), 곱셈으로 계산하는 값의 평균 (AUC) 대부분의 경우는 SD가 옳다. 산포성 SD. 통계처리시 SE. 추측통계시. triplicate를 세번이상 하는 경우는 SE써도 된다. 추측통계 모수 - 모집단을 대표. 신뢰구간 point estimate 99%CI -&gt; 더 넓어진다. (90% CI에 비해) 통계적 가설검증 (귀무가설을 기각) 검정통계량 - 가설의 옳고 그름을 판단. - 계산. talpha/2 = 3.182 이상이면 H0(귀무가설) 기각영역 Decision Tree 서열척도(ordinal scale) - 비모수적 Spearman, MW U test, Kruskal-Wallis 12.2.4 독성병리 !! 김용범: 안전성평가연구소 같은 동물인데도 병리가 다를 수 있다. (정상이 다를 수 있어.) 시험물질 관련 조직변화를 표로 작성하여 소견의 중요성을 판단 periportal vacuolation. Artifact. inadequate artifact. 부검 : 가장 중요함. gross 소견 기술: 출혈보다 discoloration. 표준화 통일화 장기중량 측정. 표준화된 방식으로 삭정( 잘라야 함. ) 같은 조직은 일관성 있게. 독성병리학자. 표준화된 표로 정리할 수 있는 능력. 대조군의 중요성 강조. 수컷 대조군- 수컷 고용량 - 저용량 순서로 한다. 현미경 진단. STP. ESTP. BSTP. JSTP. 표준화를 위한 기관들. 위치. - necrosis, neuron, hippocampus, brain 분포 - 국소, 다소성, 미만성. 병변 등급 - 주관적일 수 있다 Apoptosis- 세포막 손상 없다. necrosis - 광범위 세포막 손상 -&gt; 염증 병적과정 - 혈행 장애. 치유 및 수복 - 재생, 반흔(섬유화) 적응 기전 : 위축, 비대, 과형성, 화생. 종양: 세포조절 안됨. Peer review 아급성 혹은 만성 설치류 독성 시험. 암수 대저군 1마리(25%) 임의 5마리 고농도(10%) : 모든 슬라이드 동료 검토 Pathology working group. PWG. 병리전문가 패널. - 검토는 어떻게 수행? 각자의 의견을 투표. 의견이 틀릴때는 조율. 최종적으로 다수에 의해. 12.2.5 비임상시험결과의 임상시험 연계 !!!! 반복투여가 중요함. (NOAEL) - 대조군 대비 부작용이 유의하게 증가하지 않는 최고용량. 생물학적 유의성이 중요. (통계적 유의성이 없더라도) FDA pregnancy categories, IARC Carcinogens classification (group 1, 2, 3, 4) 반복투여 독성 시험 NOAEL을 잘 잡잡기 위해 4번의 기회가 있다. 단기(4주)~ pivotal. 단기에서 독성을 잘 봐야함. 충분히 높은 용량으로 시작한 뒤에 낮춰가는 쪽으로 해야 함. 그 반대는 참 힘들것. Safety margin = NOAEL에서의 exposure / MRHD에서의 exposure exposure가 중요하다. 비임상시험의 적용 누구를 대상으로? 최초 투여 용량은 어떻게 결정하는가? 용량 얼마씩 증량 이런 질문이 비임상시험에서 나오게 된다. Phase 1a (FIH) 임상시험대상자 (환자 vs 건강인?) 비임상시험 결과 -&gt; Seriousness? measurable? -&gt; if no, 환자관련 의약품. If yes, 건강한 시험대상자 Clinical starting dose 설정법 NOAEL/PAD based approach - estimating the maximum safe starting dose in initial clinical trials (2005-07) 초기 임상개시 가능 최고 용량 (MRSD) 각 동물 종의 NOAEL결정 HED 계산 가장 적당한 동물종 선정 safety factor 적용 MRSD의 산정 PAD고려하여 선정. Human equivalent dose (HED) calculation 사람 용량으로 외삽하는 가장 적합한 방법을 사용하여 HED 산출. (체표면적에 따라서) mg/kg을 mg/m2으로 변경해 준다. km mouse 3 rat 6 monkey 12 dog 20 human 37 h:Donkey:Monkey(rabbit):Rat:mouse = 1:2:3:6:12(mg/kg) = 동일 mg/m2 mouse 120mg/kg * 3/37 = human 10mg/kg, rat 60mg/kg = human 10mg/kg Most appropriate species selection 적당한 종을 사용해라. 잘 모를때는 더 민감한 동물 써라. HED가 더 낮은 동물을 선택하면 된다. safety factor application - 좀 낮춰서 투약하자. Default safety factor = 10 MRSD 산정(Maximum recommended starting dose) Quiz : rat 4주 반복 독성 시험에서의 NOAEL 60mg/kg. Rat는 appropriate, safety factor = 10. 60mg/kg rat km = 6, human 36, 나누면 1mg/kg이 된다. 60kg라고 보면 60mg으로 하면 된다. HED = 60mg/kg * 6/37 = human 10mg/kg MRSD = HED / SF = 10/10 = 1mg/kg = 60mg PAD (Pharmacologically active dose, PAD) 고려. PAD = 3mg/kg일때 임상 초회 용량 30으로 할 수 있다. MABEL Guideline TGN1412 (CD28-Super Mab) HED 16 mg/kg , safety factor 160 원숭이 NOAEL = 50mg/kg (BSA based HED = 16mg/kg) 원숭이 PAD = 2.5 - 25 mg/kg 원숭이 PAD-HED = 0.8 ~ 8 mg/kg , starting dose = 0.1mg/kg 사고 이후의 주장들 1. 5ug/kg 2. 3ug/kg으로 해야한다. 3. receptor occupancy - antagonist는 90% receptor occupancy가 적합. agonist는 10% receptor occupancy면 충분함. 이를 위해서는 1ug/kg면 충분함. MABEL 아마도 사람에게서 약효가 나타날 용량. Minimal anticipated biological effect level) 2007-06 새로운 가이드라인 제정됨. animal in vitro -&gt; allometric equation 산출 - animal in vivo human in vitro -&gt; 적용 . human MABEL 산출 PK-guided approach - dose대신 전신 노출(systemic exposure) 이용하여 동물 결과를 외삽(extrapolation) SD ( starting dose) = AUC * CLh NOAEL 비글에서 AUC 20ug*hr/mL 예상되는 제거율은 CLh = 15L/hr 효력의 차이는 0.1 EC50/EC50 건강인 아닌 악성 종양 환자에서의 starting dose 항암제에서.. 주료. ICH S9 57개의 임상시험을 다 분석했다. 여기서 나온 공식으로 계산. 임상-비임상 밀접한 관련. 개별 임상시험의 특성 NOAEL/PAD based approach MRSD = NOAEL * (kmanimal/kmhuman)/SF 12.3 Session II 2016-08-23 12.3.1 오믹스 기반을 이용한 독성평가 ! 최진희 서울시립대학교 systems toxicology - science+engineering+computing Multi-omics technology biological model 만들어. in silico - combination - 더 넓은 독성 개념을 얻을 수 있어 개발의 platform으로 사용할 수 있음. Exposure -&gt; molecular -&gt; cellular -&gt; organ responses -&gt; organism responses -&gt; population responses Integration is the key. New regulation (i.e. REACH), TOX21, TOX CAST adverse outcome pathway Benchmarks in Toxicology 12.3.2 독성동태 및 대사 !!! speaker: 신소영(원광대 약학대학) Efficacy 의약품의 효능 - 약물활성(Activity, A), 감수성(Sensitivity, S), 약물농도(Concentration, C) 약물의 조직에서 농도대신 약물농도에 혈중 약물 농도 변화로 효능을 기술가능. (가정) ADME toxicokinetics - 정의 : 약효를 기대하지 않는 농약이나 일반 화학물질의 체내 동태 ICH 가이드라인 독성시험기준 정의 : 독성시험 수행시 시험물질의 전신노출도 평가하기 위해 약물동태학적 자료를 산출하는 시험. Model 가장 간단한 모델만 사용할 것임 대부분의 약물은 one compartment model로 설명이 됨. Compartment model, PBPK model zero- and first-order elimination CL rate of elimination / concentration = dX/dt / Cp - 약물이 혈중에서 소실되는 속도를 혈중 약물 농도로 나누어준 값 = CL is dose divided by AUC F 약물 또는 그 활성대사체가 제제로부터 전신 순환혈로 흡수되는 속도와 양의 비율 IV는 F=1 비선형성 흡수 riboflavin(transporter GI 포화) 높은 농도에서는 모든 효소가 포화되어 0차반응에 가까워짐 낮은 혈중 농도에서는 1차반응에 가까워짐. Michaelis-Menten 소실속도 = -dC/dt = VmaxC/Km+C 약물농도가 Km보다 훨씬 클때 -dC/dt = Vmax 훨씬 작을때 -dC/dt = Vmax*C/Km 선형동태구간/비선형동태구간 12.3.3 유전독성 및 발암성 !! speaker: 김지영(안전성평가연구소) fnkim@kitox.re.kr 3 primary test battery (OECD) 화장품에 대한 독성자료 (유럽)는 안받고 있다. 화장품, 유럽은 염색체 빼고 해야함. ICH Aim of genetic toxicology testing Genotoxicigy, mutagenicity Forward mutation(braoder mutagen identification) Backward mutation(reversion) - more restricted and accurate TG490 in vitro genetic toxicology test mouse lymphoma assay TK6 assay로 불리기도 한다. Chromosomal abberation 수적 이상 구조적 이상 pre-S : chromosome abberration vs post-S : chromatid abberation In vivo genetic toxicology tests Tests for primary DNA damage(3 battery에는 안들어가.) Fast, single-strand breaks(SSB) and/or alkali-labile sites(ALS) Liver and stomach were used. (가장 중요한 장기) Sens and spec MN, CA, MLA는 specificity가 낮다. (S9 처리해서 phase I은 많이 하지만 phase II(detoxification)를 구현할 수 있는 in vitro시험은 없기 때문에 specificity 낮음) 발암성 시험 detection of potential to induce neoplastic lesions 요구되지 않는 경우 - 악성종양치료제, 3년 이내 생존 “예전거로 해주세요.” 개정된 시험이 더 고비용이기 때문에 요청하는 경우가 많다. 그러나 그렇게 하면 안된다. 12.3.4 신경독성 ! 위명복: 강원대학교 산화적 손상에 대한 신경계 취약성 항산화방어기전 중등도 낮음(catalase, GPx, vit-E) tight junction 단백감소, MMP 간접활성 microglia에 의한 ROS 및 cytokine 생산. 신경손상 형태 neuronopathy -&gt; gliosis (methyl mercury, Tins, MPTP(heroin)) myelionopathy TG: 설치류 신경독성평가, 발달 신경독성평가 Neurotoxicity screening battery Tier 1 - FOB, locomotor, GFAP ELISA, histopathology Tier 2 비동물대체법(non-animal alternative methods) 세포를 가지고 하는 것이다. 대체한계성 - 모든 것을 대체할 수 없다. Stroke, parkinson, SCI, etc.. CNS injury marker - BBB(Evan’s), microglia(OX-42), etc.. 12.3.5 식품의 위해도 평가 ! 최시내 케이앤에이컨설팅 체내로 유입되는 양이 중요함 급성 섭취 노출량 예측 잔류량이 composite 분석 결과에 해당. 노출 평가 용량-반응 관계 규명 extrapolation : high-dose -&gt; low-dose 기본 원칙 : threshold approach, non-threshold approach Non threshold -&gt; extrapolation cancer potency = Q1star = upper bound Threshold approach - NOAEL NOAEL을 활용한 RfD의 유도 NOAEL or LOAEL / UF x MF ; UF = uncertainty factor Risk characterization Threshold Hazard quotient = [exposure level] / [reference dose] exposure와 reference dose는 동일한 노출 기간에 근거 12.3.6 생식발생독성 ! 김종춘: 전남대학교 segment I, II, III (KFDA, ICH) Fertility and early embryonic development study Embryo-fetal development study Peri- and postnatal development study Segment I Stage I ~ XIV - 56일 걸린다. 같은 stage끼리 비교해야 함. Segment II 기형변이 teratogenesis 600kda 이하의 분자량이어야 태반 통과. 연골 + 경골의 염색 Segment III 한배새끼관찰, F1 성장, 행동, 생식기능시험 Key point 생식발생 위해성 급증 시험법 실험동물 종과 계통 선택 결과의 해석 종류와 특성 및 작용 기전 3Rs principle "],
["-clinical-research-science-expert-course-for-cutting-edge-drug-development.html", "Chapter 13 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development” 13.1 Drug discovery and preclinical candidate selection 13.2 Preclinical development and IND go/no-go decision (using case studies) 13.3 Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies) 13.4 Clinical Pharmacology 13.5 The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies 13.6 Open innovation in drug development 13.7 Clinical development strategy and plan workshop", " Chapter 13 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development” 교육기간 : 2016. 09. 29(목) ~ 2016. 09. 30(금) (2일) 교육시간 : 9:00~18:00 교육장소 : 서울대학교병원 암병원, 서성환홀 13.1 Drug discovery and preclinical candidate selection Be knowledgeable to project initiation processes for drug discovery as the first step Be familiar with how to identify and validate drug targets with given indication and pathology Understand each step in usual drug discovery paths mainly in the field of disease biology, assay development, high-throughput screening, medicinal chemistry, and early DMPK Identify major milestones including hit generation, hit-to-lead, and lead-to-candidate processes and their evaluation factors to make go/no go decision entering into preclinical development accordingly Exemplify several cases in actual drug discovery projects with success or failure and assess the main factors affecting success rate 13.1.1 김재은 (1ST) Discovery E-room’s law (1b 사용해서 나오는 약의 개수는 해마다 감소하고 있다.) Overall discovery process Objectives of discovery 가장 중요한건 patentable Potently and specifically recognizes target Nice metabolism and PK characteristics Target 선정. Lead to Candidate Biologics: growing sales NCE, 생체유래 biologics Oligonuc. - biologics인가? 너무 길어서 CHO Cell에서 생산해야 한다-biologics로 분류 mAb가 가장 많습니다. 그 다음 vaccine입니다. Fab만 갖는 것도 만들기도 함. bispecific 2 Arms BiTE (T cell engaging) - CD3, CD19 ADC Antibody Drug Conjugate Herceptin + DM1 toxin Immuno-oncology 약이 네개 나와있다. anti-PD-1, anti-CTLA-4 Seal breaker (Checkpoint inhibitor) + activation 유지해 주는 역할(activating receptor) restoring immunity T cell receptor + MHC CAR-T scFv - tumor cell targeting Co-stim 1, Co-stim 2 -&gt; T cell (Signal 1 and 2) Pubmed에 나와있지 않은 경우는 어떻게? Target validation해야 한다. (functional study) Library의 target성격? 10^6개의 Chemical diversity, human Ab library도 있다. 13.2 Preclinical development and IND go/no-go decision (using case studies) Speaker: 이성숙(NOV) 13.3 Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies) Speaker: 이형기(서울의대), 김한주(유한), 이장익(서울약대) Open question이 아닌 closed question해야 한다. F2F에서는 Listen해야하고 끝나고 debrief하는 과정이 반드시 필요하다. 13.4 Clinical Pharmacology Speaker: 최성준(보령), 신동훈(삼성) 13.5 The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies 13.5.1 Experience of SOP development &amp; PV training/ Sharing PV audit finding speaker: 김수원 (동아) “제약현장에서의 약물감시체계” 27개의 신약이 나왔습니다. 현재까지 PV개념이 없을때 부터 도입이 되었다. 어려움이 있었다. PMS부서에서 audit 받았다. Partner company로 부터 여러가지 이슈에 대한 지적을 받음. Audit findings (2012) Lack of reconciliation process Deficiencies in Local literature search Due deligence (2013) Not enough staff dedicated to PV Lack of Global PV DB 이런 분야를 만들어야겠다는 사장단의 의지가 있었습니다. Work scope of PV 13.5.2 Establishment and Application of Safety Database System: 백은아(보령) DB 구축 매핑 연구자에게 필요한 것은?(부산대 최상민 교수님) 10일 안에 뿌려줘야 한다. DCF보내야 하는데 속도 문제. 10일. 충실도가 높아야 한다. 13.6 Open innovation in drug development Speaker: 김한주, 남수연(유한) SGLT2 - 심혈관계 위험 낮춤 당뇨신약 CV risk assessment 필요하다 Efficacy 안나오는 경우는 human dose selection 잘 안되는 경우가 많다. Druggability - PK나와야 한다(QD면 QD에 맞게) Open innovation의 방향이 변한다. 기술을 사올때 - Target이 얼마나 novel한지? Platform technology인 경우는 feasible한지의 검토를 많이 한다. Strong science, Quality of Data 가장 중요하다. Communication, Team Work, Value Share Assets &amp; IP Review, Agreement on TPP, Valuation, In-licensing &amp; investment, Value Creation &amp; Profit Sharing 물건 사가서 아무것도 안하는 경우 많다. Clear path를 보여줘야 신뢰가 쌓인다. Feasibility test Science를 할때는 science가 중심이 되어야 한다 소렌토와 Joint Venture Company - 다음에 이야기 합시다. 항체 라이브러리를 갖고 있는 미국회사. ImmuneOncia - 10million(Yuhan) + 3 assets(미국회사, San Diego) - 개발비로 PD-1, PD-L1을 사용해서 add-on therapy에 대한 임상시험을 할 수 있다. PD-L1 kit $150000 우리나라에서 1억2천 YH25448 Case I : 사는 이야기 AZD, CO(Clovis), HM Sparing EGFR wildtype Brain Mets 항암신약산업단 - TPP를 준비했다. brain mets. 3세대는 Wild type 안건들고 selectivity가 좋더라. DMPK studies, PK-PD modeling 등 pitching했다. 7/30에 샀다. (15억) YH25448 Case II : 파는 이야기 Building up TPP Intracranial activity 클로비스의 metabolite 독성이 있다. AZD - Salt -&gt; Physicochemical property 좋아졌다. HM - Beringer가 포기한 이유 (ORR 55%) Competitive landscape T790M EGFR inhibitor 중국에는 폐암환자 많다. Alotinib보다 로컬 약을 많이 쓰고 있었습니다. 중국-뤄신 “Excellence in Science which translates into substantial Clinical Benefit” 유한양행, 중국 뤄신에 비소세포폐암 표적치료제 신약후보물질 기술이전 13.7 Clinical development strategy and plan workshop Understand purpose of clinical development plan and its key components Evaluate and analyses target indications and identify unmet therapeutic needs Assess market potential and competition around target indications Describe product profile with relevant evidence developed for target indications Create project plan including key milestones and budget Evaluate and apply regulatory aspects underpinning clinical development Draft target product profile(TPP) with proposed indications and promotional claims Identify and assess program risks and develop mitigation strategies 13.7.1 Course intro - Understanding TPP and HCV 안종호(MSD) TPP and HCV Efficacy, Tolerability, Convenience, Other - TPP 13.7.2 Candidate selection through PoC 임경수(차의대), 이승환(서울의대) 1,4형에 대한 medical unmet need 많다. protease inhibitor, polymerase inhibitor 우리도 Durg X 개발. Protease inhibitor만들자. 비임상시험결과. FIH study를 B병원에서 진행하기로 함. 질문1. FIH연구는 어떠한 목적을 갖고 수행? 우선순위? Endpoint들은 어떤것? 자료1. HED 이 용량 사람에게 줬을때. FIH Endpoint - Safety/tolerability (적절한 방법으로 적절한 시간에) Metabolite에 대한 PK 비임상에서 규명되지 않은 metabolite나올 수도 있음. for early proof-of-concept : surrogate biomarker ex vivo PD (challenge test) - 연구소와 같이 해볼 수 있다. (탐색적 목적) 항생제 같은 경우 모델이 잘 정립되어 있음. 항바이러스제는 모델이 정립안되어있어. Hybrid로도 할 수 있다. (일정 용량까지는 자원자로, 최대용량에서 환자 대상으로?) Parallel vs cross-over MTD 찾는게 목적이 아니다. Go/No-go 40mg*2.5배 8.8이상도 유지 (20,40에서도 개발 가능할 것임) Renal transport - mechanistic problem 연구소에 요청해서 탐색해봐야 함 Affecting factors (Safety, efficacy, PK, marketability) 13.7.3 Late phase Development &amp; Commercialization 이소라(Abbvie), 문준식(SK케미칼) NDA 제출시에 pivotal phase III 적어도 두개는 해야 합니다. 13.7.4 국내 사례 소개 및 질의/응답 손지웅(한미약품) 2010~ 한미 한국은 early phase development 하는 기회가 늘어나고 있습니다. 특히 oncology 측면에서 그러합니다. Target - Hit - Lead - Lead opt - Pre-nom. - Early clinical development - Lead optimization 되는 시점부터 시작된다고 봅니다. Animal to human 예측 못하는 영역이 많습니다. Interaction between investigator, regulartor, and sponsor is important. Pneumonia - 예전과 현재 관점의 변화 Cancer - pathology -&gt; genetics Establish realistic expectation! 기대값을 낮춰야 함. Strategy to overcome innovation crisis Open Innovation이 요즘의 화두입니다. 열린 깔데기로 확률을 높이는 것을 목적으로 합니다. 실제로 구현하기 어렵습니다. Virtual operation Evolution to open innovation : lean and mean organization Adaptive clinical trial design "],
["the-2nd-a3-pharmacometrics-symposium.html", "Chapter 14 The 2nd A3 Pharmacometrics Symposium 14.1 Young Scientist Session 14.2 Application Session 14.3 Regulation", " Chapter 14 The 2nd A3 Pharmacometrics Symposium Harmonization of Regulatory view about Pharmacometrics and sharing experience on population approach Date: 14th October, 2016 (Friday) Location: Teok-Seong-Hwa Hall (Room No. 413-1), College of Pharmacy (Building No. W6), Chungnam National University, Daejeon, Korea Sponsored by: PAGK, PAGJa and PCPC 14.1 Young Scientist Session 14.1.1 Modeling of mycoplasma tuberculosis biomarkders for cure Speaker: Yookwhan Noh 14.1.1.1 Introduction Mycobateria taxonomy Myco. Tuberculosis MOTT VPC results impreved by several steps Model validation by bootstrap 14.1.1.2 Gene Xpert ETA distribution from Xpert : Skewed to left. 14.1.2 Integrative PKPD modling and simulation of Amenamevir for treatment of recurrent genital herpes Akitsuga Takada HSV-1, HSV-2(Genital) PKPD analysis 14.1.3 Model Based Meta-Analysis to quantify and compare the efficacy of non-hormonal drugs on menopausal Hot flashes Lujin Li (PCPC) Hot flashes - low levels of estrogen SSRI, SNRI, Gabapentin, clonidine Tx : HRT, Non-hormonal drugs - regulators of central neurotransmitters, phytoestrogens Lancet 2008 - limitation : speed of onset MBMA - useful (Model based meta analysis) Pubmed, cochrane library Hot flash, Emax model 15,5,4,~ (39 studies) The effects Soy isoflavones Placebo Run-in design is better. 14.1.4 Dosing optimization in obesity using pharmacometrics approach: population PK and PD of meropenem in non-obese, obese and mobidly obese patients Eun Kyung Chung (PAGK) PK model development Stepwise model development Covariate model building Model selection criteria : goodness of fit plots, RSE, OFV Structural CMT PK model Observed conc - individual predicted concentration Visual predictive checks - quite good MIC - probability of target attainment PD analysis - CrCl&lt;50 14.2 Application Session 14.2.1 The application of pharmacometrics in individual therapy in China Speaker: Zheng Jiao (PCPC) Java PK for dashtop Bayesian Dose Estimation Drugs - Immunosuppressant, vanco, anti-epil Non adhereence in chronic disease Individualized therapeutic range Many dashboard systems in China 14.2.2 PD model fo Bayesian Prediction of myelosuppression rpofiles based on routine clinical data after gemcitabine and carboplatin treatment Speaker: Yoshitaka Yano (PAGJa) GEM, CDDP - PLT, RBC, WBC NM7.3 FOCE Bootstrap resampling / estimation Correlation plots of IPRED vs DV VPC - 90% predictive interval 14.2.3 Modeling and validating chronic pharmacological manupulation of circadian rhythms Speaker: Jaekyung Kim(PAGK) Transcriptional negative clock Entrain.org Sensitive to dosing timing, light 180 variables Okazaki (2014), Symptom differs (2010) 14.2.4 Application of PK/PD modeling and simulation in antiviral drug development Speaker: Kun Wang (PCPC) Varal dynamic model HIV replication cycle Target - Virus - Infected cell T (CD4) I (Infected CD4) Lopinavir/Ritonavir (LPV/RTV) Influenza - oseltamivir, oseltamivir carboxylate 14.2.5 pharmacometrics in clinical practice: pop PK analysis of febuxostat in patients with severe renal impairment Speaker: Daiki Hira Febuxostat - renal execretion + biliary Allopurinol -&gt; Oxypurinol - renal execretion 14.3 Regulation 14.3.1 The new Japanese guideline on population PK and PD analysis Speaker: Yusuke Tanigawara (PAGJa) Structural, Error, Covariate model Model diagnosis - 각 스텝마다 해야 된다. Model qualification(or evaluation / validation)이 중요하다. Final stage -&gt; Bootstrap, External validation, VPC 14.3.2 How to increase the number of population PK analysis reports submitted to MFDS in Korea Speaker: Howard Lee (PAGK) 의약품 개발 시 집단 약동학 활용 Dose optimization and ethnic bridging Technical pharmacometrics trap Impact Technical modelling 14.3.3 EMA regulations on meling issues Speaker: Jaewoo Kim (PAGK) Guidance for industry 14.3.4 Recent examples of impact of pharmacometrics in decision making Speaker: Jee Eun Lee (USA) Parieotide - somatostatin analogue (high affinity for sstr5) -&gt; somatostatin analogue (Novartis) 600ug BID failed to meet the pre-specified primary efficacy endpoint Flat E-R for efficacy / steep E-R for hyperglycemia Good for some - urine cortisol high patients 14.3.4.1 Secukinumab Chronic Plaque Psoriasis Interindividual variability (PD, PK) Secukinumab (Cosentyx) - target population Https://en.wikipedia.org/wiki/Secukinumab (Novartis) Example of dose optimization Body weight - significant covariate - conc decreases with body weight (stratified by 90kg) Conc are higher in patients &lt; 90kg 90kg 이상의 사람에게 150mg 추가 용량을 투여하는게 적합한가? IL-17(A) - Etanercept, infliximab, adalimumab(humira, shallow), ustekinumab = biologics IgA, 4 Phase III, (2 of them were pivotal study) PMC - post marketing commitment The higher conc. =&gt; the higher incidence of infections (tolerable) 14.3.4.2 Edoxaban (흥미로운 약물) NOAC - New Oral Anti-coagulants (4th) 1st rivaroxaban, 2nd dabigatran(issue-EMA), 3rd apixaban Ace Meeting? Normal - Mild - Moderate Exposure - response relationships (Efficacy-Stroke, safety-bleeding) Benefir-risk relationship is not novel. (Dabigatran: RE-LY trial) Exposure-response relationship PK matching. Identifying covariates prior to Phase 3 "],
["asrm-2016.html", "Chapter 15 ASRM 2016 15.1 Plenary lectures 15.2 Prize Oral 15.3 Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women 15.4 Scientific Congress Prize Paper Session 2 15.5 Oral Presentation", " Chapter 15 ASRM 2016 ASRM 2016은 미국생식의학회에서 주최하는 생식의학 관련 가장 큰 학회입니다. https://drive.google.com/open?id=0B7BS_yg2ja1EeUFxWkxFWVU3dEE 15.1 Plenary lectures 15.1.1 Plenary 2 speaker: Camran Nezhat, M.D. Lectureship in Innovations in Medicine speaker: Diana W. Bianchi, M.D. Tufts University School of Medicine (NICHD director, soon-to-be) Maternal Plasma DNA Sequencing Noninvasive prenatal genetic testing using analysis of cell-free DNA in maternal plasma has translated to and transformed clinical care. importance of positive and negative predictive values 15.1.2 Plenary Lecture 3 : The importance of Long-acting reversible contraception (LARC) speaker: Jeffrey F. Peipert (Indiana University) Unintended pregnancy = High-risk pregnancy Less likely to seek prenatal management Huge difference among countries - Sexual activity = Similar (US and Sweden) Teen birth 는 감소하고 있다. Common contraceptive method - OCP, Sterilization , Condom, Vasectomy IUD, DMPA, Implant - highly effective LNG-IUS ~ 5y, Copper ~ 10y, Implnat - 3y Myths - infection, infertility, pain, cancer, Providers - litigation fear Safety IUD does not cause PID (Only first month) IUD does not cause infertility (Chlamydia - infertility) Etopic pregnancy - Actually reduce! Actually lower risk of endometrial, cervical cancer Poor candidates for IUD - puerperal sepsis, post septic abortion, unexplained vaginal bleeding, current cervitis, chlamydia Adolescents - encourage use of dual Etonogestrel implant - subdermally implant (NEXPLANON) inhibits ovulation &lt;1% didn’t vary by BMI status discontinuation - bleeding irregulatities Contraceptive Choice Project Promote LARC use 50% believe IUC is safe 10,000 participants (4 years) CHOICE study 2000 teenagers 75% chose LARC. NEJM published (2 papers) Very reliable - especially teenagers Decreased repeated abortion Race disparity can be minimized. Edutcation, Access, Costs &amp; LARC-friendly providers Dissemination strategies - Short videos Summary Unintended pregnancy and teen pregnancy continue to be important health problems in the United States. Long-acting reversible contraception (LARC) is one strategy that has proven to be effective, yet underutilized. 15.1.3 Plenary 4 speaker: Jay Ross Kaplan, Ph.D. Wake Forest School of Medicine CV (CHD and stroke) - not just for men WISE study - endogenous estradiol in premenopausal women w or wo CHD Conclusions from epidemiology of sex differences in CHD Pre- and sugically postmenopausal monkeys Subclinical ovarian dysfunction - relatively common in premenopausal monkeys - precocious acceleration of atherosclerosis. Exogenous hormones (OCs) mitigate this effect. Estrogen treatment immediately following ovariectomy inhibits atheosclerosis; delayed treatment ineffective - perhaps because lesions are larger. CHD risk in pre- and early post-menopausal women - ELITE tiral and numerous re-examinations of existing trials. 15.1.4 Plenary 5 speaker: Jan Deprest, M.D., Ph.D., F.R.C.O.G. - University of Leuven Fetal surgery Obstetical endoscopy - TTTS Angiogram showed “Third” circulation. “Chorangiopagus” - donor (oligohydramnios) recipient (polyhydramnios) Ultrasound screening programs can pick up congenital malformations, of which some are eligible for prenatal surgical repair. Some procedures are possible by fetoscopy, while others require a hysterotomy. impact of fetal surgery on the future reproductive life of the mother MOMS trial - 12mo outcomes (prenatal surgery, postnatal surgery) - uterine dehiscence (10%) !!!! Congenital diaphragmatic hernia - lethal pulmonary hypoplasia - fetoscopic surgery (tracheal occlusion) Future Fetal surgery - fails in ~40% of cases -&gt; Novel target discovery - gene expression analysis Explorer candidate medical Tx. -&gt; Viagra Conclusion Fetoscopy is a clinical reality (few materal Cx &lt;1%) Open surgery (high materal morbidity) 15.1.5 Plenary 6 Update on Congenital Adrenal Hyperplasia Maria I. New, M.D. -&gt; Icahn School of Medicine at Mount Sinai SRY (Y chromosome) Sertoli - MIF (Mullerian Inhibiting Factor -&gt; supress tubes) -&gt; Mullerian regression Leydig cells -&gt; testosterone -&gt; DHT (Penis, scrotum) 17OH Progesterone (CAH screening) bone age advancement, rapid growth Classical diseases Congenital adrenal hyperplasia is a common inherited form of adrenal insufficiency due to mutations (genetic defects) in the genes coding for several enzymes needed to produce vital adrenal cortex hormones. such as drug therapy with androgen-blocking effects and growth hormone to delay puberty, as well as surgical options, including prenatal therapy. 15.1.6 Plenary 7 - Why Parents Matter (Epigenetically): Genomic Imprinting in Health and Disease Marisa S. Bartolomei, Ph.D. 15.1.7 Plenary 8: AUA Bruce Stewart Memorial Lecture: The Futures of (Male(Reproductive)) Medicine Craig Niederberger, M.D., F.A.C.S. stackoverflow - advance all elements in a Range in Swift WOLFRAM Mathematica second order differential mathematics Wolfram Alpha Raspberry Pi RASPBERRY PI ZERO: THE $5 COMPUTER Medical Therapy - prior to TESE the future of reproductive medicine Urine pressure checker by Raspberry Pi Sperm analysis by automated machine Future shock by Alvin Toffler 15.2 Prize Oral 15.2.1 mTOR inhibitors preserve fertility in a murine model : a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy Kara Goldmann (NYU) Schneider lab diminished ovarian reserve PI3K -&gt; AKT -&gt; mTORC1 mTORC1 inhibitors (Everolimus) - breast cancer mTOR inhibitor 단독은 부작용 있지만, cyclophosphamide가 ovarian reserve를 보존할 수 있다 rodent experiment AMH - (when increased, ovarian reserve decreased) Cytoxan단독은 AMH 낮추나 복합은 여전히 높아져 있음 RAD INK daily CY(cyclophosphamide) RAD+CY INK+CK mTOR inhibitors preserved fertility 15.2.2 Verification of accuracy &amp; safety for ovarian reserve assessment with optical coherence tomography using mouse ovary Seido Takae establishment of standard follicle imaging Safety of OCT - No impact on IVF outcome Clinical Trial - vitrification - aplastic anemia (15/F) Young cancer or POI patient can be benefited (Ovariectomy) Laparoscopy 15.2.3 O-6 RANDOMIZED CONTROLLED TRIAL OF LOW (5%) VS. ULTRALOW (2%) OXYGEN TENSION FOR IN VITRO DEVELOPMENT OF HUMAN EMBRYOS speaker: Daniel Kaser 5% - oviduct 2% - uterine How about culturing environment? 배양도 같은 방법으로 해야 하나? Design : 5% O2 (D1-D3) -&gt; 5% vs 2% O2 (D4~ ) Primary endpoint: Embryo stage and grade Secondary endpoint: Spent media analyses These findings support our hypothesis that blastocyst yield and quality may be superior when O2 tension is reduced from 5% to 2% on day 3, thereby recapitulating the O2 environment in vivo. 15.3 Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women panel: Yun-shang Piao, Ph.D., R.A.C., Rhonda M. Hearns-Stewart, M.D., Shelley R. Slaughter, M.D., Ph.D., Monica Garcia, Ph.D., Michael T. Bailey, Ph.D. 15.3.1 Richard D. McFarland, M.D., Ph.D. OTAT - Office of Tissues and Advanced Therapies Cellular therapies, Cancer vaccines etc Human cells, Tissues (HCT/Ps) Two regulatory tiers “361 HCT/P” Drugs, devices and/or biological products 2667 registered (mostly HPC, blood bank) Relavant communicable disease agents or disease (RCDADs) - HIV-1,2, HBV, HBC, syphilis, Donor eligibility (DE) determination DE exception (Cells and tissue for autologous use, by sexually intimate partner..) Recent final guideline Syphilis Testing - FDA-licensed, approved or cleared donor screening tests WNV(West Nile Virus) Testing - licensed NAT donor screening test (June - Sep) HBV NAT - FDA-licensed NAT donor screening test ZIKV Screening - immediate implementation guidance 지금까지는 Subpart C, 지금부터는 Subpart A 15.3.2 Rhonda - CDER Drug review process speaker: Rhonda Important regulatory milestones 1906 - Pure Food Drugs Act 1938 - FDC (The Act) 1951 - Durham-Humphrey Amendment - prescription drug (habit forming, potentially harming drug) 1962 - Kefauver-Harris Drug Amendment - all new drugs must also establish efficacy 1984 - Hatch 1992 - prescription drug user fee act (PDUFA 프두파) 2007 - FDA Amendments Act (FDAAA 파다) CDER responsibility Investigational New Drug (IND) - how can an unapproved new drug be tested in clinical trials? IND - need or not? - Lawfully marketed? Off-label? Treat patient? Cover, TOC, Introductory statement and general plan, IB, Tox, 30 day safety review - are the risk to the clinical participant acceptable? adequate safety monitor? - Clinical Hold (deficiency) NDA - efficacy, safety - 505(b)(1), 505(b)(2) Evaluation that all requirements for submission have been met and that NDA is well orgenized Multi-disciplinary approach - Multiple levels 74-day letter Physician labeling - PLR (Physician labeling reult) REMS (risk evaluation and mitigations strategies) - REMS for NDA - medication guide, communication plan, implementation ETASU (elements to assure safeuse) - specific training Phase 4 : postmarketing requirements information on regulation of medical products intended for assisted reproduction Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Devices and Radiological Health (CDRH) 15.3.3 CDRH (Center for Devices and Radiological Health) Monica Medical device - isn’t metabolized. Classification - Class I (Low risk)-premarket review not required, II (Intermediate) - Petri dishes etc - typically required, III (High) - PMA required. OB/GYN devices branch - ART devices, vaginal lubricants etc… 21 CFR Parts 884.6100 - 6200 subpart G Class II - substantially equivalence to another marketed devices. - Same intended use, technological characteristics MOA, Materials/components, Engineering schematics, Design specifications 510(k) submission - Device description, Labeling (False/misleading claims, instructions for use) Sterilization (Method, validation, package integrity) Shelf-life (duration of proposed shelf-life, performance), biocompatibility (patient contact, duration of contact) Electical safety, electromagnetic compatibility ART II special controls - design spec, MEA(Mouse embryo assay), HSSA(human sperm survival assay), endotoxin testing 510(k) outcomes - SE (substantially equivalence) | NES, try again | NSE Device clearance after SE outcome De Novo - the newest way for devices to come to market When come to FDA? Presubmission program for interactive feedback from FDA - regulatory pathway, Investigation Device Exemption (IDE) fda.gov/Tranining/CDRHlearn 15.3.4 Endometriosis, Tuesday EXPO theater ESHRE, European Society of Human Reproduction and Embryology (2014), WES(World Endometriosis Society), Consensus on current management of endometriosis (2013) - Consensus on current management of endometriosis. The case for surgical diagnosis of endometriosis - Diamond Michael Diamond, MD - Pelvic pain DDX - Endometriosis, fibroids, adenomyosis, adhesions, PID (gynecologic) IBS, Intestitial cystitis, fibromyalgia (non-gynecologic) Most accurate technique for diagnosis -&gt; laparoscopy with histological confirmation The case for clinical diagnosis of endometriosis - Surrey mean - dianosis, 9.3y, 5 patients Ultrasound findings - 81% PPV (K - 0.58) Description of pain (throbbing …) Symptoms of women undergoing surgery -&gt; dysmenorrha etc (high) Can response to medication be used to diagnose endometriosis? GnRH agonist or OCs. Dr. Surrey’s proposed diagnostic algorithm Discussion Diamond - Ix of GnRH agonist - absense of pathology apparent by noninvasive diagnostic modalities Surrey - Ix of laparoscopy - suspicious or symptomatic adnexal mass, failure to respond to second-line therapy, management of fertility as primary concern, clear evidence of deeply invasive disease 15.4 Scientific Congress Prize Paper Session 2 15.4.1 O-91 PREOVULATORY PROTEIN RESTRICTION (PPR): DISRUPTED AMINO ACID (AA) KINETICS AND MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE RAT OOCYTE speaker: Amy Schutt - Baylor College Maternal dietary intake critically supports the oocyte through maturation, fertilization and until embryo genome activation. PPR -&gt; profound changes in amino acid metabolism and COC mitochondrial structure and function in the rat. Amino acid kinetics in the oocyte decreased ability to increase antioxidant precursor production lack of effective compensation in the setting of protein starvation. LP oocyte is vulnerable to oxidative stress as it cannot increase GSH production. abnormal COC mitochondrial ultrastructure and altered oocyte expression of genes related to mitochondrial biogenesis. 15.4.2 O-92 EFFECTS OF RESVERATROL ON POLYCYSTIC OVARY SYNDROME speaker: Antoni Duleba (University of California, San Diego) Hyperandrogenism is the central feature of PCOS isolated ovarian theca-interstitial cells demonstrated that resveratrol, a natural polyphenol, inhibits mRNA expression of Cyp17a1 and reduces androgen production evaluated endocrine and metabolic effects of resveratrol on women with PCOS. Prospective double-blind, randomized, placebo-controlled trial. clinical trial evaluating the effects of resveratrol on PCOS Resveratrol significantly reduces serum levels of testosterone and DHEAS effect on ovarian as well as adrenal androgen production. improvement of insulin sensitivity and a decline of insulin level 15.4.3 O-93 GENOME-WIDE DNA METHYLATION CHANGES IN MOUSE ZYGOTES ASSOCIATED WITH SUPEROVULATION speaker: Bo Yu (University of Washington, Seattle) Assisted Reproductive Technologies (ART) procedures can result in abnormal methylation of some imprinted genes in early embryos. genome-wide effect to identify DNA methylome changes in pre-implantation mouse embryos after ovarian hyperstimulation 15.4.4 O-94 CAN WE EXPECT TO IMPROVE AGE AT MENOPAUSE PREDICTIONS WITH REPEATED AMH MEASUREMENTS? speaker: Annelien de Kat (University Medical Center Utrecht, Utrecht, Netherlands) high AMH -&gt; late menopause, low AMH -&gt; early menopause AMH decline rate Repeated measures of AMH levels Anti-M€ullerian hormone (AMH) levels are considered to be an **indicator of ovarian aging unraveled longitudinal decline trajectories of AMH with age. 1,857 women enrolled in the prospective, population-based Doetinchem Cohort Study, with a known age at natural menopause (ANM) picoAMH assay (AnshLabs) in a total of 7,666 plasma samples Time to menopause modeled with the use of mixed model analyses, taking non-linear changes of AMH with age into account for each individual longitudinal study confirms the overall association of AMH levels with time to menopause, while taking into account individual AMH changes with time 15.5 Oral Presentation 15.5.1 O-229 THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE (Hugh Taylor) PPT 15.5.2 O-230 DIRECT AND INDIRECT COSTS ASSOCIATED WITH ENDOMETRIOSIS-RELATED SURGERY AMONG EMPLOYED WOMEN IN THE US Speaker: Ahmed Soliman surgery 10% endometriosis treatment of endometriosis by surgery is common economic burden - MarketScan database surgery cohort and non-surgery cohort direct, indirect expenditures, multivariale analysis (GLM) Hysterectomy $3k, laparoscopy $3k 18k all cause surgery vs 8k non-surgery observational study 15.5.3 O-231 NEW PROCEDURE FOR THE ENDOMETRIOSIS DIAGNOSIS speaker: Xavier Santamaria mouse model - midventral incision, suture with peritoneal cavity GFP - endometriotic cells, CD45 - leukocytes LGR5 - transmembrane orphan receptors - microarray에서 control과 두드러진 차이 보임. human : in silico study : affymetrix HG U133 Plus 2.0 Arrays Co-localization with LGR5, none in donor vs high in endometriosis patient LGR5+ endometriosis vs LGR5- endometriosis Monocyte –(differentiation)–&gt; macrophage, monocyte-derived DCs Conclusion LGR5+ cells co localized in stroma of human eutopic endometrium immune system, adhesion molecules, migration pathways were differnetially expressed. 15.5.4 O-232 Elagolix on endometrium PPT "],
["kscpt-2016-fall.html", "Chapter 16 KSCPT 2016 Fall 16.1 Therapeutics : New target 16.2 Drug development I 16.3 Drug development II 신상구 (차바이오컴플렉스)", " Chapter 16 KSCPT 2016 Fall 대한임상약리학회 2016년도 추계학술대회 일 시 : 2016년 11월 17일(목)~18일(금) 장 소 : 전북대병원 임상연구지원센터 2층 새만금홀 16.1 Therapeutics : New target 16.1.1 A new target for HIV-1 / AIDS drug speaker: 유지창 ((주)에빅스젠 / 가톨릭의대) integrase inhibitor (4th generation) 개발중인 치료제 NtRTI, NNRTI, INSTI etc Targeting packaging. Nucleocapsid (NC) protein - important for RNA packaging Tox, body disposition Traditional - Zinc chelator/ejector Brand-new - NC and viral RNA attachment inhibition -&gt; packaging and utilitzation First-in-class Phase I, SAD Question: 동물실험? Answer: Not done Quesiton: Screening을 어떤식으로 했는가? Answer: 직접 개발함 16.1.2 New drug target for osteoporosis: GPR120 speaker: 김현주 (경북의대) 골다공증 RANKL (OB) - RANK(OC) - Homeostasis Reduced estrogen (menopause) -&gt; OC strengthened. bisphosphonate - OC inhibitor Denosumab (anti-RANKL) SERM - raloxifene -&gt; anti-resorption - 약함 bisphosphonate - 악골 괴사 fatty acid-sensing GPCRs as therapeutic targets - GPR120 (receptor) - endogenous ligand - DHA, EPA GPR120 and diabetes OC development (MQ is a precursor) - MQ proliferation -&gt; Differentiation -&gt; fusion -&gt; polarization -&gt; resorption Characteristics - Ruffled border. Polarization - cytoskeletal organization - actin cluster and ring formation GPR120 - upregulated during OC differentiation GPR120 signaling enhances apoptosis in mature OC. - 파골세포가 죽는다. M-CSF-induced ring formation can be inhibited by GPR120. in vivo research? - Jung-Min Koh (Asan Medical Center) Beneficial effect of FFA4 on bone mass in an ovariectomized model. Question: assay with Omega3, Answer: Yes, we did. 16.1.3 Strategy for Anti-Cancer Target speaker: 신영기 (서울약대) Immuno-oncology First-line treatment : Nivolumab T cell activation process - tumor Ag -&gt; Immunosuppression by PD-L1 Positive and negative signals - CTLA4, PD-1 checkpoint pathway Lung cancer - 종전에는 immunogenic하지 않다고 봤기 때문에 놀라웠다. Type-I Interferon (IFN-alpha/beta) - Antitumor effect +, ADCC enhancement, APC activation, etc (Semin Oncol. 2014; 41:623-636) How to increase productivity of IFN? - Carbiferon - Rebif, Avonex보다 우수함. Sensitization of glycoengineered IFNb cFLIP - death receptor - siRNA Development of anti-ERBB2 Ab + IFNb - Ab-CK conjugation system ADCC 유지됨. CDC 는 원래 없다. Enhanced ADCC effects, immune response activation, enhancer R27T direct anti-cancer TANS (Therapeutic antibody DB) Patent 16.1.4 재발자궁경부암 항암화학방사선 온열동시치료 speaker: 이선영 (전북대학교병원) CCRT - Recurrence -&gt; 7-14% - what better Tx? Hyperthermia -&gt; direct cell killing 전도치료 -&gt; GLUT2 channel + Radiofreq. = Protein damage ciplatin 단독요법, paclitaxel add. Adenoca. FIGO IIIb - 7cm Cx Ca. Safety - not different. 자궁경부암 혈류측정 (78% 증가) - Tyrosine kinase inhibitor, 넥사바 (sorafenib) Question : 어떻게 온열치료 대상 환자를 선정하나?, Answer : 이건 reprospective research? Question : 들어가는 energy의 양을 정량화할 수 있나?, Answer: Watt, Joule이 계산이 된다. 16.2 Drug development I 16.2.1 Non-clinical considerations for FIH speaker: 김봉태 MTD, NOAEL MRHD - safety assessment of metabolites 16.2.2 임상약리학 주도 환자 대상 초기임상시험의 경험과 전망 speaker: 이형기 (서울대학교병원) http://snuhclinicaltrials.com/kr/ Fast move to patients : hybrid approach Optimize exposure Drug X - reduced adipogenesis lypophillic - 식사랑 같이하면 exposure 높아져. Mechanistic biomarkers Total fat amount - CT volume TNF-alpha (200mg), surprizingly no effects (400,800mg) Early detection of efficacy signal, identified potential biomarkers Opportunities More pharmas want fast transition to patients, clinicians inexperienced, commercial early hpase CROs lack patient access, patient access Hint of Efficacy Variability and sensitivity, inter-rater consistency Study powered? - if not powered, what will you do with the results? Biomarkers Enrollment and study management - ward support Are we ready? - OK for routine care &amp; management of patient with mild to moderate disease AE assessment - causality - more clinical practice System support required, stay out of the safe zone, be prepared. 16.2.3 The Contribution of Clinical Pharmacologist in Global Drug Development: Real Examples from a Big Pharma speaker: 김용호 (Parexel) industry perspective Governing bodies review, regulatory agencies interactions, due diligence Big Pharma Clin Phar Group Dose-regimen selection or optimization hepatotoxicity - Acetaminophen - CIx Compound #1 - strong inhibitor of CYP2C8, CYP2C9 and ibuprofen is substrate of CYP2C9 Compound #1 + Ibuprofen -&gt; Modeling -&gt; It’s okay. 16.3 Drug development II 신상구 (차바이오컴플렉스) 16.3.1 BA/BE 임상시험 결과분석 시 고려사항: 분산투여 vs 추가시험 speaker: 김정렬 (삼성서울병원) 분산투여 추가시험 (MFDS, 2007) - 추가시험 mean squared error - estimator of intra-subject variability 90% 신뢰구간 산출에 이용. 길이를 봐야한다. 따라서 합치기 힘들다. Interaction Study가 일관적이지 않다. F-test - 분산을 비교하는 방법. - two consistency tests must be done 변경된 캐나다 규정 2012 일관성 입증 할 필요없다. 점추정치 기법이기 때문에 대상자수 많아지면 equivalence에 가까워져 Two-stage design - 1종 오류를 보정. priori power - 가정에 근거한 검정을 했을때 정해진 대상 post-hoc Patvin D, Pharmaceutical Statistics 2008 - Method B (health Canada) or C 1종 오류 보정. 윤리적 관점 - 개체내 변이가 작은 약물임에도 24명으로 수행. 분산투여(일관성 입증 안해도 돼) vs 추가시험 (일관성 입증 해야) 추가시험은 일관성 입증: penalty있어야 함. Question: 투여 - fixed or random effect (분산투약) - 배교수님 random 16.3.2 The use of pharmacometrics for drug development in Korea speaker: 한승훈 (가톨릭의대) Seoul - Bio International Convention, SCIC, Bio 외국에서 가져오는 것이 방향 Modeling and Simulation, Biomarker Decision-making with M&amp;S Data -&gt; Learn -&gt; Apply -&gt; Decision MBDD (Model-based Drug Developments) Pharma + Governmental support 표준적인 data - Q-fitter - Oct 2016 On the job training Licensing in and out methodology vs subject ㈜씨엔알리서치(대표 윤문태)는 20년의 임상 노하우 및 인프라를 적극 활용하기 위해, 가톨릭 계량약리학연구소(PIPET)와 국내 유일의 전문 계량약리학 상용 서비스기관인 ㈜큐피터(Q-fitter Inc.)를 설립했다고 밝혔다. 큐피터는 씨엔알리서치가 100% 출자해 10월 27일 법인 등록을 마쳤으며, 큐피터의 대표이사는 씨엔알리서치 윤문태 대표이사가 맡게 된다. 씨엔알리서치는 이번 법인 설립을 통해, 비임상자료를 이용한 초기임상시험 설계, 이전 임상 결과를 기반으로 한 다음 단계 임상시험 설계, 임상결과를 해석한 허가용 자료 작성 등 신약개발 전 과정에 걸쳐 후보물질의 약동-약력학 모델링 및 시뮬레이션 분석 및 자문 서비스를 시작한다. 신약 개발에 필수적이지만 독자적으로 계량약리학 전문성을 갖추기 어려운 국내외 제약 및 바이오 기업 등이 이 서비스의 주요한 수요자가 될 전망이다. 씨엔알리서치는 이를 계기로, 신약개발사들의 후보물질 관련 정보의 활용도 극대화, 후속 단계 설계 최적화 및 후보 물질 가치 제고 등을 도모할 수 있을 것으로 기대되며, 이는 각 개발사의 신약 개발 역량 제고는 물론 국내 전체의 신약개발 및 임상시험 관련 경쟁력을 강화할 수 있는 중요한 기반기술이라고 설명했다. 윤문태 대표이사는 “큐피터는 글로벌 기준에 부합하는 서비스를 국내외 제약 바이오 기업들에 제공하는 것을 목표로, 신약개발 생태계 조성을 위해 적극적으로 사업을 추진할 계획”이라고 밝혔다. 씨엔알리서치는 1997년 설립돼 세계 임상시험의 트랜드 분석을 통한 임상시험의 질 향상과 서비스 개선에 매진, 매년 30% 이상 꾸준히 성장하며 2014년, 2015년 연속 국내에서 가장 많은 매출을 달성한 한국 최고 수준의 임상시험수탁기관이다. 중국 지사(현지 법인) 운영 및 아세안지역 진출 등 아시아 전역을 대상으로 하는 신시장 개척을 통한 해외 인허가 및 임상 서비스를 제공하고 있고 있으며, 임상시험교육(Academy), 약물부작용감시(Pharmacovigilance), 품질관리(QA), 중앙모니터링(CM), 메디컬어드바이징(MA), IT 기반 e-Clinical 솔루션 등 고객의 니즈에 맞춘 신 사업 개발을 통해 폭 넓은 임상 솔루션을 제공하고 있다. 16.3.3 Fatal BIA 10-2474 Phase I Clinical Trial : What Can We Learn? speaker: 임경수 (차의과대학 분당차병원) TGN1412 - Lancet 2006 MABEL - minimal anticipated biological effect level FAAH - BIA 10-2474 NEJM - FAAH -&gt; Acute neurologic Sx. MRI - brain damages! BJCP - BIA - not high-risk compounds - No MABEL Non-proportionality regarding dose and time Off-target effect Efficacy보이는 것만 개발해야 한다 / Dose selection and escalation / Pride "],
["will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html", "Chapter 17 2016-11-18 Will big data and data science reshape the horizon of drug development?, If so, how? 17.1 JSCPT 17.2 How can clinical pharmacology facilitate collaboration between the drug development industry and academia, particularly in the Asian-Pacific region?", " Chapter 17 2016-11-18 Will big data and data science reshape the horizon of drug development?, If so, how? 17.1 JSCPT Chair : Hiroshi Watanabe(president of JSCPT). Tae Sun Park(Chonbuk National University) 17.1.1 대규모 약물 유도 전사체 정보 기반 항암 신약 재창출 speaker: Wan Kyu Kim Ewha Womans University 17.1.2 Big data platform for multi-national data collaboration speaker: Rae Woong Park (Ajou University School of Medicine), veritas@ajou.ac.kr Distributed Research Network with common data model Common Data Model - pSCANNER, OHDSI, NYC-CDRN OHDSI ohdsi.org http://github.com/OHDSI ATLAS - http://www.ohdsi.org/web/atlas/ Question: CDM 17.1.3 Yoshinori Ochiai (Pharmaceuticals and Medical Devices Agency) 17.1.4 How big data (national registry data) can be a game changer? speaker: Hiroshi Ohtsu (National Center for Global Health and Medicine) 10:20~10:30 Q &amp; A 10:30~10:45 coffee break 17.2 How can clinical pharmacology facilitate collaboration between the drug development industry and academia, particularly in the Asian-Pacific region? Chair : Kazutaka Shimoda(Dokkyo Medical University), Yil-Seob Lee(GSK) 10:45~11:05 Collaboration with Clinical Pharmacology in New Drug Development : Oncologist’s View Do-Youn Oh (Seoul National University College of Medicine) 11:05~11:25 Drug development by connecting academy to venture company JungWon Woo (Genexine) 11:25~11:45 Examples of collaborations with local government and academia for Global FIH studies in Japan Masako Nakano (Eli Lilly Japan K.K.) 11:45~12:05 Strategy for efficient drug development utilizing functions of ARO Yuji Kumagai (Kitasato University) 12:05~12:15 Q &amp; A 12:15~13:30 점 심 시 간 IT : CDISC DM ICT 남문석 (인하대학교 의과대학) 13:30~13:55 Case Report Form using Acrobat PDF 배균섭 (울산대학교 의과대학) 13:55~14:20 Big Data 소개 및 주의점 임지연 (동국대학교 의과대학) 14:20~14:45 Mobile App in clinical Trial 김민걸 (전북대학교 의과대학) 14:45~15:10 IT 활용 임상시험 효율화 이승환 (서울대학교 의과대학) 15:10~15:30 coffee break 15:30~16:00 Young Scientist (8명) 16:00~16:30 16:30~17:00 17.2.1 Thyroid Thyroidectomy - Ca homeostasis Hypoalbuminemia - Disease progression model - NONMEM AIC? VPC n = 1142 "],
["section.html", "Chapter 18 2017-03-20", " Chapter 18 2017-03-20 speaker: Dr. Park Hypothesis-free (GWAS) or hypothesis-driven Genomics-based approaches (top-down approach) Finding the association (various ways) Array - Sequencing: 2 methods &gt;70 % CGH - compa geno hybrid "],
["reference.html", "Chapter 19 Reference", " Chapter 19 Reference "]
]
